nct_id stringlengths 11 11 | title stringlengths 23 300 | phase stringclasses 9
values | status stringclasses 13
values | study_type stringclasses 2
values | is_expanded_access bool 2
classes | sponsor stringlengths 5 100 | summary stringlengths 45 4.76k | interventions listlengths 1 12 | start_date stringlengths 0 10 | url stringlengths 44 44 | target_entities listlengths 0 5 | locations listlengths 0 104 | contact_phone stringlengths 0 29 | contact_email stringlengths 0 41 | eligibility dict | mechanism_summary dict |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
NCT04654689 | Impact of the Combined Treatment of Liposomed Polyphenols With G04CB02 on the ALS Patients | PHASE2 | COMPLETED | INTERVENTIONAL | false | Fundación Universidad Católica de Valencia San Vicente Mártir | Amyotrophic lateral sclerosis (ALS) is a disease of an inflammatory nature, which causes progressive muscle weakness associated with cognitive and behavioural disorders. Pathogenically, it is characterised by loss of oxidative control, excitotoxicity due to excess glutamate and intestinal dysbiosis. In the absence of c... | [
{
"type": "DIETARY_SUPPLEMENT",
"name": "Liposomed polyphenols resveratrol and curcumin"
},
{
"type": "OTHER",
"name": "Placebo for liposomed resveratrol and curcumin"
},
{
"type": "DIETARY_SUPPLEMENT",
"name": "Isocaloric Diet"
},
{
"type": "DRUG",
"name": "G04CB02"
},... | 2021-11-20 | https://clinicaltrials.gov/study/NCT04654689 | [
"oxidative_stress",
"glutamate_excitotoxicity",
"neuroinflammation"
] | [
{
"facility": "José Enrique de la Rubia Ortí",
"city": "Valencia",
"state": "Valencia",
"country": "Spain",
"status": "",
"lat": 39.47391,
"lon": -0.37966
}
] | {
"criteria": "Inclusion Criteria:\n\n* All ALS patients, over 18 years of age and with a clear diagnosis and symptomatology of ALS since at least 6 months.\n\nExclusion Criteria:\n\n* Women under 50 years of age and childbearing age.\n* Tracheotomy patients.\n* Patients with invasive or non-invasive ventilation with... | {
"compound": "Liposomed polyphenols (resveratrol and curcumin) with G04CB02",
"targeting_mechanism": "Combination of antioxidant polyphenols and an undefined agent (G04CB02) targeting oxidative stress and inflammation in ALS pathogenesis.",
"targeting_mechanism_pmid": "38473944",
"animal_results": "unknown",
... | ||
NCT07423494 | Personalized Antisense Oligonucleotide Therapy for A Single Patient With CHCHD10 ALS (nL18576) | PHASE1, PHASE2 | NOT_YET_RECRUITING | INTERVENTIONAL | false | n-Lorem Foundation | This research project entails delivery of a personalized antisense oligonucleotide (ASO) drug designed for a single participant with amyotrophic lateral sclerosis (ALS) due to a pathogenic variant in CHCHD10 | [
{
"type": "DRUG",
"name": "nL-CHCHD-001"
}
] | 2026-03 | https://clinicaltrials.gov/study/NCT07423494 | [
"CHCHD10"
] | [
{
"facility": "Mayo Clinic",
"city": "Rochester",
"state": "Minnesota",
"country": "United States",
"status": "",
"lat": 44.02163,
"lon": -92.4699
}
] | {
"criteria": "Inclusion Criteria:\n\n* Informed consent/assent provided by the participant (when appropriate), and/or participant's parent(s) or legally authorized representative(s)\n* Ability to travel to the study site and adhere to study-related follow-up examinations and/or procedures and provide access to parti... | {
"compound": "nL-CHCHD-001",
"targeting_mechanism": "Personalized antisense oligonucleotide (ASO) designed to target pathogenic CHCHD10 variant in a single ALS patient.",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurposed",
"repurpos... | ||
NCT04516096 | A Compassionate Use Protocol of AMX0035 for Treatment of Patients With Amyotrophic Lateral Sclerosis (ALS) | PHASE2, PHASE3 | COMPLETED | INTERVENTIONAL | false | Amylyx Pharmaceuticals Inc. | The protocol is intended to provide extended treatment with AMX0035 to patients who previously participated in an Amylyx sponsored study of AMX0035 for ALS. | [
{
"type": "DRUG",
"name": "AMX0035"
}
] | 2020-11-22 | https://clinicaltrials.gov/study/NCT04516096 | [
"TARDBP"
] | [
{
"facility": "Forbes Norris MDA/ALS Research Center - California Pacific Medical Center",
"city": "San Francisco",
"state": "California",
"country": "United States",
"status": "",
"lat": 37.77493,
"lon": -122.41942
},
{
"facility": "Massachusetts General Hospital",
"city": "... | {
"criteria": "Inclusion Criteria:\n\n* Any patient who has completed follow-up in an Amylyx sponsored trial of AMX0035 for the treatment of ALS will be eligible to enroll into this Protocol\n* Capable of providing informed consent\n* Capable and willing to follow trial procedures\n* Capable and willing of travelling... | {
"compound": "AMX0035",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT06177431 | An Open Label Extension Study of Monepantel in Individuals With Motor Neurone Disease | PHASE1 | COMPLETED | INTERVENTIONAL | false | Neurizon Therapeutics Limited | This study is a multicenter, 12-month open label extension study, following Phase 1 Study MON-2021-001, with a single dose of monepantel (MPL) once daily (QD) for the treatment of individuals with MND. | [
{
"type": "DRUG",
"name": "Monepantel"
}
] | 2024-02-13 | https://clinicaltrials.gov/study/NCT06177431 | [
"pyruvate_dehydrogenase_kinase_inhibition"
] | [
{
"facility": "Macquarie University",
"city": "Sydney",
"state": "New South Wales",
"country": "Australia",
"status": "",
"lat": -33.86785,
"lon": 151.20732
},
{
"facility": "Calvary Health Care Bethlehem",
"city": "Melbourne",
"state": "Victoria",
"country": "Austral... | {
"criteria": "Inclusion Criteria:\n\n1. Signed informed consent obtained prior to initiation of any study specific procedures and treatment.\n2. Individuals who are willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.\n3. Able to swallow study drug tablets.\... | {
"compound": "Monepantel",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT00420719 | Motor-Point Stimulation for Conditioning the Diaphragm of Patients With Amyotrophic Lateral Sclerosis (ALS) | NA | UNKNOWN | INTERVENTIONAL | false | Synapse Biomedical | The overall goal of this research is to delay the respiratory decline of patients with Amyotrophic Lateral Sclerosis (ALS) thereby increasing their lifespan by conditioning the diaphragm with laparoscopically placed electrodes.
This device currently holds an Investigational Device Exemption No. G040142 in the United S... | [
{
"type": "DEVICE",
"name": "Intramuscular diaphragm electrodes"
}
] | 2004-10 | https://clinicaltrials.gov/study/NCT00420719 | [] | [
{
"facility": "Forbes Norris - California Pacific Medical Center (CPMC)",
"city": "San Francisco",
"state": "California",
"country": "United States",
"status": "",
"lat": 37.77493,
"lon": -122.41942
},
{
"facility": "Stanford University Medical Center",
"city": "Stanford",
... | {
"criteria": "Inclusion Criteria:\n\n* Age 18 or older\n* Participants with familial or sporadic ALS diagnosed as laboratory-supported probable, probable, or definite according to the World Federation of Neurology El Escorial criteria will be eligible\n* Bilateral phrenic nerve function clinically acceptable as demo... | {
"compound": "unknown",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurposed",
"repurposed_from_pmid": ""
} | ||
NCT05095571 | A Trial of Nicotinamide/Pterostilbene Supplement in ALS: The NO-ALS Extension Study | NA | RECRUITING | INTERVENTIONAL | false | Haukeland University Hospital | Amyotrophic lateral sclerosis (ALS) is a serious rapidly progressive disease of the nervous system. The mean survival from the time of diagnosis is 2.5 years. Apart from Riluzole, there is no effective treatment. Care of advanced ALS will have a cost of 4-8 million NOK (Norwegian kroner) per year.
Research i.a. from t... | [
{
"type": "DIETARY_SUPPLEMENT",
"name": "EH301 (Nicotinamide Riboside/Pterostilbene)"
}
] | 2021-10-07 | https://clinicaltrials.gov/study/NCT05095571 | [
"nad_metabolism",
"histone_deacetylase_inhibition"
] | [
{
"facility": "Haukeland University Hospital",
"city": "Bergen",
"state": "",
"country": "Norway",
"status": "RECRUITING",
"lat": 60.39299,
"lon": 5.32415
},
{
"facility": "Nordlandssykehuset HF",
"city": "Bodø",
"state": "",
"country": "Norway",
"status": "NOT_YE... | +4755975063 | obty@haukeland.no | {
"criteria": "Inclusion Criteria:\n\n* Patients who fulfilled the criteria for the NO-ALS study and have completed the study will be proposed inclusion in the NO-ALS extension study protocol. Patients from both arm 1 and arm 2 in the NO-ALS study will be allowed inclusion in the prolongation study\n\nExclusion Crite... | {
"compound": "EH301 (Nicotinamide Riboside/Pterostilbene)",
"targeting_mechanism": "Increases NAD+ levels and histone deacetylation enzyme (sirtuin) activity to enhance mitochondrial proteostasis and neurogenesis in motor neurons.",
"targeting_mechanism_pmid": "31929756",
"animal_results": "Nicotinamide Ribosi... |
NCT00415519 | Efficacy and Safety Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis (ALS) Who Met Severity Classification III | PHASE3 | COMPLETED | INTERVENTIONAL | false | Shionogi | The primary objective of this study is to evaluate the efficacy of 60mg of MCI-186 via intravenous drip once a day in patients with ALS whose severity is classified as grade III, based on the changes in the revised ALS functional rating scale (ALSFRS-R) scores after 24 weeks administration in double-blind, placebo-cont... | [
{
"type": "DRUG",
"name": "MCI-186"
},
{
"type": "DRUG",
"name": "Placebo of MCI-186"
}
] | 2006-12-31 | https://clinicaltrials.gov/study/NCT00415519 | [
"oxidative_stress"
] | [] | {
"criteria": "Inclusion Criteria:\n\n* Patients who are defined as \"definite ALS,\" \"probable ALS\" or \"probable-laboratory-supported ALS,\" met diagnostic criteria revised EL Escorial for Airlie House.\n* Patients who cannot take at least one action of eating a meal, excreting, or moving with oneself alone, and ... | {
"compound": "MCI-186",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT00353665 | Memantine for Disability in Amyotrophic Lateral Sclerosis (MEDALS) | PHASE2, PHASE3 | COMPLETED | INTERVENTIONAL | false | University of Lisbon | The purpose of this trial is to study the effect of Memantine (uncompetitive, moderate affinity, NMDA receptor antagonist that binds to the NMDA receptor channel, and regulates the calcium influx into the neurons), a drug used to treat Alzheimer´s disease, on the progression of Amyotrophic Lateral Sclerosis (ALS). Mema... | [
{
"type": "DRUG",
"name": "Memantine (Ebixa)"
},
{
"type": "DRUG",
"name": "riluzole"
},
{
"type": "DRUG",
"name": "Placebo"
}
] | 2005-07 | https://clinicaltrials.gov/study/NCT00353665 | [
"GRIN1"
] | [
{
"facility": "Department of Neurology - Hospital de Santa Maria",
"city": "Lisbon",
"state": "",
"country": "Portugal",
"status": "",
"lat": 38.72509,
"lon": -9.1498
}
] | {
"criteria": "Inclusion Criteria:\n\n* Definite or probable disease - revise El Escorial criteria\n* Normal blood tests\n* Riluzole treatment during 1 month or more\n* EMG in accordance with El Escorial criteria\n\nExclusion Criteria:\n\n* Other diseases (such as PNP)\n* Both ADM muscles \\< 3 on MRC scale\n* Conduc... | {
"compound": "Memantine",
"targeting_mechanism": "Uncompetitive, moderate affinity NMDA receptor antagonist that binds to the NMDA receptor channel and regulates calcium influx into neurons.",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknow... | ||
NCT00355576 | Combination Therapy Selection Trial in Amyotrophic Lateral Sclerosis | PHASE2 | COMPLETED | INTERVENTIONAL | false | Columbia University | The objective of this study is to compare two combinations of drugs, minocycline and creatine or celecoxib and creatine, in a phase II trial designed to determine which combination is more effective for ALS. | [
{
"type": "DRUG",
"name": "Celecoxib"
},
{
"type": "DRUG",
"name": "Creatine"
},
{
"type": "DRUG",
"name": "Minocycline"
}
] | 2006-07 | https://clinicaltrials.gov/study/NCT00355576 | [
"neuroinflammation",
"oxidative_stress"
] | [
{
"facility": "Phoenix Neurological Associates",
"city": "Phoenix",
"state": "Arizona",
"country": "United States",
"status": "",
"lat": 33.44838,
"lon": -112.07404
},
{
"facility": "UCLA",
"city": "Los Angeles",
"state": "California",
"country": "United States",
... | {
"criteria": "Inclusion Criteria:\n\n* A clinical diagnosis of possible, laboratory-supported probable, probable or definite ALS, according to modified EL Escorial criteria\n* FVC greater or equal to 60% at the screening visit\n* Symptom onset within 5 years\n* 21 to 85 years of age\n* If patients are taking riluzol... | {
"compound": "Celecoxib",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT00397423 | G-CSF Treatment for Amyotrophic Lateral Sclerosis: A RCT Study Assessing Clinical Response | PHASE2 | COMPLETED | INTERVENTIONAL | false | Peking University | This study will examine the effectiveness of G-CSF in treating patients with amyotrophic lateral sclerosis (ALS) - a fatal neurological degenerative disease that causes adult-onset, progressive motor neurons loss in the spinal cord, brain stem and motor cortex. Patients develop progressive wasting and weakness of both ... | [
{
"type": "DRUG",
"name": "Granulocyte Colony Stimulating Factor"
},
{
"type": "DRUG",
"name": "NS"
}
] | 2006-12 | https://clinicaltrials.gov/study/NCT00397423 | [
"neuroprotection"
] | [
{
"facility": "Dongsheng Fan",
"city": "Beijing",
"state": "Beijing Municipality",
"country": "China",
"status": "",
"lat": 39.9075,
"lon": 116.39723
}
] | {
"criteria": "Inclusion Criteria:\n\n* All subjects must have a verifiable diagnosis of ALS of 0.5 to 2 years' duration. The diagnosis must be supported by the Revised Criteria of the World Federation of Neurology. The grades of diagnosis must be clinically definite ALS or clinically probable ALS.\n* All subjects mu... | {
"compound": "Granulocyte Colony Stimulating Factor (G-CSF)",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT03427086 | Safety and Tolerability of High Dose Biotin in Patients With Amyotrophic Lateral Sclerosis | PHASE2 | COMPLETED | INTERVENTIONAL | false | American University of Beirut Medical Center | This is a randomized double blinded randomized 2:1 study. The duration of the study is 6 month. The safety and tolerability of high doses of biotin (300 mg/ day) will be compared to placebo in patients with amyotrophic lateral sclerosis. Patients will be evaluated at baseline, 3, and 6 month. The primary outcome will b... | [
{
"type": "DRUG",
"name": "Biotin"
},
{
"type": "DRUG",
"name": "Placebo Oral Tablet"
}
] | 2018-01-29 | https://clinicaltrials.gov/study/NCT03427086 | [
"biotin"
] | [
{
"facility": "American univeristy of Beirut medical center",
"city": "Beirut",
"state": "",
"country": "Lebanon",
"status": "",
"lat": 33.89332,
"lon": 35.50157
}
] | {
"criteria": "Inclusion Criteria:\n\n* Amyotrophic Lateral Sclerosis (ALS) volunteers must be diagnosed within 3 years prior to participation as having possible, probable, or definite ALS, either sporadic or familial according to modified El Escorial criteria\n* Age 18-80, able to provide informed consent, and compl... | {
"compound": "Biotin",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT01938495 | Diaphragm Pacing System (DPS) In Participants With Amyotrophic Lateral Sclerosis (ALS) | PHASE2 | COMPLETED | INTERVENTIONAL | false | Barrow Neurological Institute | The study is being conducted to determine if DPS treatment for people with ALS and hypoventilation is associated with improved survival or diaphragm function.
The primary objective of the study is to conduct a multi-center, randomized controlled clinical trial comparing standard of care (control) to diaphragm stimulat... | [
{
"type": "DEVICE",
"name": "NeuRx® Diaphragm Pacing System™ (DPS)"
}
] | 2013-08 | https://clinicaltrials.gov/study/NCT01938495 | [
"neuromuscular_transmission"
] | [
{
"facility": "Barrow Neurological Institute",
"city": "Phoenix",
"state": "Arizona",
"country": "United States",
"status": "",
"lat": 33.44838,
"lon": -112.07404
},
{
"facility": "Cedars-Sinai Medical Center",
"city": "Los Angeles",
"state": "California",
"country": ... | {
"criteria": "Inclusion Criteria:\n\n1. Age 21 years or older.\n2. Sporadic or familial ALS diagnosed as definite, probable or possible ALS as defined by revised El Escorial criteria.\n3. Evidence of hypoventilation at Screening with at least one of the following:\n\n 1. Maximal static inspiratory pressure (MIP) \... | {
"compound": "NeuRx Diaphragm Pacing System (DPS)",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurposed",
"repurposed_from_pmid": ""
} | ||
NCT00876772 | Olanzapine for the Treatment of Appetite Loss in Amyotrophic Lateral Sclerosis (ALS) | PHASE2, PHASE3 | COMPLETED | INTERVENTIONAL | false | Charite University, Berlin, Germany | Amyotrophic Lateral Sclerosis (ALS) is an adult neurodegenerative disease that is caused by a selective degeneration of the motor nerve cells in the cortex and myelon. As a result of motor neurodegeneration, a progredient paralysis of the extremities and of the speaking, swallowing, and breathing musculature develops. ... | [
{
"type": "DRUG",
"name": "Olanzapine"
}
] | 2011-03 | https://clinicaltrials.gov/study/NCT00876772 | [
"olanzapine"
] | [
{
"facility": "Charité - Universitätsmedizin, Berlin, Germany",
"city": "Berlin",
"state": "",
"country": "Germany",
"status": "",
"lat": 52.52437,
"lon": 13.41053
}
] | {
"criteria": "Inclusion Criteria:\n\n* Patients between the ages of 18 and 80 years old\n* Clinical diagnosis of definitive, probable, and possible ALS (revised El Escorial Criteria) or diagnosis of the clinical ALS-variants of Progressive Muscle Atrophy (PMA)\n* Sporadic and familial ALS\n* Beginning of symptoms of... | {
"compound": "Olanzapine",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT00004771 | Phase II Study of Leuprolide and Testosterone for Men With Kennedy's Disease or Other Motor Neuron Disease | PHASE2 | COMPLETED | INTERVENTIONAL | false | National Center for Research Resources (NCRR) | OBJECTIVES:
I. Evaluate the effects of androgen suppression with leuprolide and androgen replacement with testosterone enanthate on muscle strength in men with Kennedy's disease or other motor neuron disease. | [
{
"type": "DRUG",
"name": "leuprolide"
},
{
"type": "DRUG",
"name": "testosterone"
}
] | 1992-10 | https://clinicaltrials.gov/study/NCT00004771 | [
"Androgen receptor"
] | [] | {
"criteria": "PROTOCOL ENTRY CRITERIA:\n\n--Disease Characteristics--\n\nMen aged 18 and over with motor neuron disease, i.e.:\n\n* X-linked spinal and bulbar muscular atrophy (Kennedy's disease)\n* Confirmed by androgen receptor, exon-1 mutation genotype\n* Amyotrophic lateral sclerosis\n* Spinal muscular atrophy\n... | {
"compound": "leuprolide and testosterone",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT05860244 | Effect of Salbutamol on Walking Capacity in Ambulatory ALS Patients | PHASE2 | UNKNOWN | INTERVENTIONAL | false | Assistance Publique - Hôpitaux de Paris | Preclinical and clinical data strongly suggest that administration of salbutamol in ALS patients may improve walking capacity related to motor fatigue by enhancing neuromuscular transmission. Salbutamol may exert a neuroprotective effect and slow down the progression of clinical signs and symptoms. The main objective o... | [
{
"type": "DRUG",
"name": "Salbutamol"
},
{
"type": "DRUG",
"name": "Placebo"
}
] | 2024-09 | https://clinicaltrials.gov/study/NCT05860244 | [
"neuromuscular_transmission"
] | [
{
"facility": "Hôpital Pitié Salpêtrière",
"city": "Paris",
"state": "",
"country": "France",
"status": "",
"lat": 48.85341,
"lon": 2.3488
}
] | 01 42 16 58 70 | g.querin@institut-myologie.org | {
"criteria": "Inclusion Criteria:\n\n* Subjects who meet the revised El Escorial criteria for probable or definite sporadic ALS\n* Adult patients between 18 and 75 years of age\n* Patients who are ambulatory and able to perform the 6MWT and quantitative muscle testing at screening (ALSFRS-R-walking = 3)\n* Patients ... | {
"compound": "Salbutamol",
"targeting_mechanism": "β2-adrenergic agonist that enhances neuromuscular transmission and may exert neuroprotective effects.",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} |
NCT04248465 | An Efficacy and Safety Study of Ravulizumab in ALS Participants | PHASE3 | TERMINATED | INTERVENTIONAL | false | Alexion Pharmaceuticals, Inc. | The purpose of the study is to assess the efficacy and safety of ravulizumab for the treatment of adult participants with ALS. | [
{
"type": "DRUG",
"name": "Placebo"
},
{
"type": "BIOLOGICAL",
"name": "Ravulizumab"
}
] | 2020-03-30 | https://clinicaltrials.gov/study/NCT04248465 | [
"complement_pathway"
] | [
{
"facility": "Barrow Neurological Institute",
"city": "Phoenix",
"state": "Arizona",
"country": "United States",
"status": "",
"lat": 33.44838,
"lon": -112.07404
},
{
"facility": "Neuromuscular Research Center and Clinic",
"city": "Phoenix",
"state": "Arizona",
"coun... | {
"criteria": "Key Inclusion Criteria:\n\n1. A diagnosis of sporadic or familial ALS, defined by the El Escorial criteria (possible, laboratory-supported probable, probable, or definite ALS).\n2. ALS onset ≤ 36 months from Screening.\n3. Documented meningococcal vaccination not more than 3 years prior to, or at the t... | {
"compound": "Ravulizumab",
"targeting_mechanism": "Complement cascade inhibitor targeting the complement system's role in motor neuron degeneration.",
"targeting_mechanism_pmid": "27056040",
"animal_results": "Complement activation has been found in animal models of ALS, including the SOD1G93A mouse model, wi... | ||
NCT03690791 | Efficacy of Cannabinoids in Amyotrophic Lateral Sclerosis or Motor Neurone Disease | PHASE3 | UNKNOWN | INTERVENTIONAL | false | Gold Coast Hospital and Health Service | This is a randomised, double-blind, placebo controlled study on a cannabis-based medicine extract (MediCabilis CBD Oil), in patients with Amyotrophic Lateral Sclerosis or Motor Neurone Disease. Participants will be randomised in a 1:1 ratio to receive MediCabilis CBD Oil or placebo oil. The treatment duration is 6 mont... | [
{
"type": "DRUG",
"name": "MediCabilis CBD Oil"
},
{
"type": "DRUG",
"name": "Placebo Oil"
}
] | 2019-01-09 | https://clinicaltrials.gov/study/NCT03690791 | [
"Cannabinoid receptor"
] | [
{
"facility": "Gold Coast Hospital and Health Service",
"city": "Gold Coast",
"state": "Queensland",
"country": "Australia",
"status": "",
"lat": -28.00029,
"lon": 153.43088
}
] | {
"criteria": "Inclusion Criteria:\n\n1. Affected by ALS/MND, either of definite or probable according to the El Escorial revised criteria\n2. Can provide written informed consent\n3. Able and willing to comply with all study requirement\n4. Male or female, ages 25-80 years old\n5. Onset of first symptom within the l... | {
"compound": "MediCabilis CBD Oil",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT06230562 | DIAGALS: Relation Between Tar DNA Binding Protein(TDP)-43 et Nrf-2 in ALS: a Track to Improve Diagnosis and Prognosis of the Disease | NA | UNKNOWN | INTERVENTIONAL | false | University Hospital, Tours | In response to oxidative stress, cells activate the Nrf-2 pathway, which induces translation of its target genes and corresponding proteins involved in the antioxidant response. This explains the interest in the Nrf-2 pathway in the pathophysiology of Amyotrophic lateral sclerosis (ALS), supported by the results of sev... | [
{
"type": "BIOLOGICAL",
"name": "Blood sample"
},
{
"type": "BIOLOGICAL",
"name": "Blood sample"
}
] | 2024-02 | https://clinicaltrials.gov/study/NCT06230562 | [
"TARDBP",
"NFE2L2",
"oxidative_stress"
] | [] | +33247474665 | e.mousset@chu-tours.fr | {
"criteria": "Patients group :\n\nInclusion Criteria:\n\n* Men and women ≥ 18 years old\n* Person affiliated to a French social security scheme or equivalent\n* ALS diagnosed according to El Escorial criteria\n* Diagnosis of ALS \\< 6 months\n* Onset of symptoms \\< 2 years\n* Signed informed consent\n\nNon-inclusio... | {
"compound": "unknown",
"targeting_mechanism": "The Nrf-2 pathway in response to oxidative stress, modulated by TDP-43, to induce antioxidant proteins.",
"targeting_mechanism_pmid": "34663413",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": "... |
NCT02469896 | A Trial of Tocilizumab in ALS Subjects | PHASE2 | COMPLETED | INTERVENTIONAL | false | Barrow Neurological Institute | This research study is being done to find out if tocilizumab, also known as Actemra™, can help with Amyotrophic Lateral Sclerosis (ALS). The investigators also want to find out if tocilizumab is safe to take without causing too many side effects.
Currently ALS has no cure and 2 modestly effective treatment to slow the... | [
{
"type": "DRUG",
"name": "Tocilizumab"
},
{
"type": "OTHER",
"name": "Placebo"
}
] | 2015-11 | https://clinicaltrials.gov/study/NCT02469896 | [
"IL-6"
] | [
{
"facility": "Barrow Neurological Institute",
"city": "Phoenix",
"state": "Arizona",
"country": "United States",
"status": "",
"lat": 33.44838,
"lon": -112.07404
},
{
"facility": "University of Kansas Medical Center",
"city": "Kansas City",
"state": "Kansas",
"countr... | {
"criteria": "Inclusion Criteria:\n\n* Participants with ALS (El Escorial criteria: possible, laboratory-supported probable, probable or definite)\n* Capable of providing informed consent and complying with trial procedures.\n* High inflammatory profile of PBMC gene expression\n* Upright SVC ≥40% of predicted value ... | {
"compound": "Tocilizumab",
"targeting_mechanism": "IL-6 receptor antagonist that inhibits the immune-mediated death of motor neurons.",
"targeting_mechanism_pmid": "28612258",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT05542576 | Study of AMDX-2011P as a Retinal Tracer in Subjects With Neurodegenerative Diseases Associated With Amyloidogenic Proteinopathy | PHASE1, PHASE2 | COMPLETED | INTERVENTIONAL | false | Amydis Inc. | The purpose of this research study is to assess safety and tolerability of a single intravenous (given through a vein) dose of the investigational retinal tracer AMDX-2011P in patients with neurodegenerative diseases (Parkinson's disease and ALS). | [
{
"type": "DRUG",
"name": "AMDX2011P"
}
] | 2022-08-24 | https://clinicaltrials.gov/study/NCT05542576 | [
"amyloidogenic_proteinopathy"
] | [
{
"facility": "Eye Research Foundation",
"city": "Newport Beach",
"state": "California",
"country": "United States",
"status": "",
"lat": 33.61891,
"lon": -117.92895
},
{
"facility": "Brittany NIcholl",
"city": "Pasadena",
"state": "California",
"country": "United Sta... | {
"criteria": "Inclusion Criteria:\n\nFor Subjects with Parkinson's Disease\n\n1. Clinically established Parkinson's disease based on Movement Disorder Society (MDS) Clinical Diagnostic Criteria for Parkinson's disease (Table 8) and a modified Hoehn \\& Yahr scale of 1-3 (Table 9).\n2. No suspected atypical parkinson... | {
"compound": "AMDX-2011P",
"targeting_mechanism": "Retinal tracer for imaging amyloidogenic proteinopathy in neurodegenerative diseases.",
"targeting_mechanism_pmid": "36834792",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT02548663 | Sport Therapy and Osteopathy Manipulative Treatment in ALS | NA | COMPLETED | INTERVENTIONAL | false | University of Milano Bicocca | This project assessed muscle oxidative metabolism and fatigue in patients affected by amyotrophic lateral sclerosis (ALS) undergoing to three months of individualized cardiovascular and strength training. Muscle oxidative metabolism and strength will be assessed by non-invasive methods, such as near-infrared spectrosco... | [
{
"type": "OTHER",
"name": "Sport therapy"
},
{
"type": "OTHER",
"name": "Osteopathic treatment"
}
] | 2014-06 | https://clinicaltrials.gov/study/NCT02548663 | [
"oxidative_stress"
] | [] | {
"criteria": "Inclusion Criteria:\n\n* diagnosis of ALS\n* early stages of disease\n* able to perform exercise with major muscle groups.\n\nExclusion Criteria:\n\n* non-invasive ventilation (NIV)\n* tracheostomy\n* coronaropathy\n* ongoing infectious diseases\n* cognitive deficits.",
"sex": "ALL",
"min_age": "18... | {
"compound": "unknown",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurposed",
"repurposed_from_pmid": ""
} | ||
NCT00140452 | Phase II Study Using Thalidomide for the Treatment of ALS | PHASE2 | COMPLETED | INTERVENTIONAL | false | Dartmouth-Hitchcock Medical Center | The use of Thalidomide in patients with ALS who have disease progression. | [
{
"type": "DRUG",
"name": "Thalidomide"
}
] | 2005-02 | https://clinicaltrials.gov/study/NCT00140452 | [
"TNF-alpha",
"angiogenesis"
] | [
{
"facility": "Dartmouth Hichcock Medical Center",
"city": "Lebanon",
"state": "New Hampshire",
"country": "United States",
"status": "",
"lat": 43.64229,
"lon": -72.25176
}
] | {
"criteria": "Inclusion Criteria:\n\n* Clinically proven ALS\n* Disease duration less than or equal to 5 years\n* ALSFRS-R score equal to or greater then 30\n\nExclusion Criteria:\n\n* Patients with known deep venous thrombosis or hyper coagulable state will be excluded\n* Patients with FVC less than 80%",
"sex": ... | {
"compound": "Thalidomide",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT03127514 | AMX0035 in Patients With Amyotrophic Lateral Sclerosis (ALS) | PHASE2 | COMPLETED | INTERVENTIONAL | false | Amylyx Pharmaceuticals Inc. | The CENTAUR trial was a 2:1 (active:placebo) randomized, double-blind, placebo-controlled Phase II trial to evaluate the safety and efficacy of AMX0035 for the treatment of ALS. | [
{
"type": "DRUG",
"name": "AMX0035"
},
{
"type": "OTHER",
"name": "Placebo"
}
] | 2017-06-22 | https://clinicaltrials.gov/study/NCT03127514 | [
"TARDBP",
"FUS"
] | [
{
"facility": "Barrow Neurological Institute",
"city": "Phoenix",
"state": "Arizona",
"country": "United States",
"status": "",
"lat": 33.44838,
"lon": -112.07404
},
{
"facility": "UC Irvine Medical Center",
"city": "Orange",
"state": "California",
"country": "United ... | {
"criteria": "Key Inclusion Criteria:\n\n1. Male or female, aged 18-80 years of age\n2. Sporadic or familial ALS diagnosed as definite as defined by the World Federation of Neurology revised El Escorial criteria\n3. Less than or equal to 18 months since ALS symptom onset\n4. Capable of providing informed consent and... | {
"compound": "AMX0035",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT02152449 | Oral Nutritional Supplementation in Amyotrophic Lateral Sclerosis (ALS) Patients | NA | COMPLETED | INTERVENTIONAL | false | University Hospital, Limoges | The purpose of this study is to determine whether an early oral nutritional supplementation (ONS) in amyotrophic lateral sclerosis (ALS) patients is effective on the treatment of this rapidly progressive disease. | [
{
"type": "DIETARY_SUPPLEMENT",
"name": "Oral nutritional supplementation"
}
] | 2014-07 | https://clinicaltrials.gov/study/NCT02152449 | [
"nutritional_status"
] | [
{
"facility": "Service de Neurologie",
"city": "Limoges",
"state": "",
"country": "France",
"status": "",
"lat": 45.83362,
"lon": 1.24759
}
] | {
"criteria": "Inclusion Criteria:\n\n* Patients ≥18 years of age, diagnosed with ALS (\\<2 months before inclusion) according to Airlie House criteria : definite, probable, or probable laboratory supported;\n* Time between first symptoms and diagnosis less than 18 months\n* Sporadic or familial cases\n* Patient agre... | {
"compound": "Oral nutritional supplementation",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurposed",
"repurposed_from_pmid": ""
} | ||
NCT00386464 | Noninvasive Ventilation in ALS Patients With Mild Respiratory Involvement | PHASE2, PHASE3 | COMPLETED | INTERVENTIONAL | false | Johns Hopkins University | Non-invasive ventilation or BiPAP®, which is a form of breathing support delivered through a facemask, is a successful treatment for the respiratory complications of amyotrophic lateral sclerosis (ALS). It has been shown to prolong survival, improve quality of life, and improve cognitive function. It is widely used amo... | [
{
"type": "DEVICE",
"name": "noninvasive positive pressure ventilation"
}
] | 2002-04 | https://clinicaltrials.gov/study/NCT00386464 | [] | [
{
"facility": "Johns Hopkins University School of Medicine",
"city": "Baltimore",
"state": "Maryland",
"country": "United States",
"status": "",
"lat": 39.29038,
"lon": -76.61219
}
] | {
"criteria": "Inclusion Criteria:\n\n* Probable or definite ALS by El Escorial criteria\n* age \\>17 years\n* FVC \\>60\n* minimal respiratory symptoms (no orthopnea or dyspnea at rest)\n* ability to provide informed consent\n\nExclusion Criteria:\n\n* Presence of another neurodegenerative disease\n* arterial CO2 ab... | {
"compound": "unknown",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurposed",
"repurposed_from_pmid": ""
} | ||
NCT05797701 | A Study in Healthy Adult Male & Female Participants to Assess the Amount of the Study Medicine (SAR443820) Absorbed by the Body, When Given Orally in Fasted Condition as a Tablet Versus as a Capsule (Part 1) and When Given Orally as a Tablet in Fasted Condition Versus as a Tablet After Food (Part 2) | PHASE1 | COMPLETED | INTERVENTIONAL | false | Sanofi | Part 1:
This is an open label, balanced randomized, single dose, 2-sequence, 2-period (period 1 and period 2), 2-treatment crossover (between Treatment A and Treatment B for Part 1), study part to determine the relative bioavailability of SAR443820 in tablet formulation versus capsule formulation under fasted conditio... | [
{
"type": "DRUG",
"name": "SAR443820"
},
{
"type": "DRUG",
"name": "SAR443820"
}
] | 2021-07-28 | https://clinicaltrials.gov/study/NCT05797701 | [] | [
{
"facility": "Prism Research-Site Number:8400001",
"city": "Saint Paul",
"state": "Minnesota",
"country": "United States",
"status": "",
"lat": 44.94441,
"lon": -93.09327
}
] | {
"criteria": "Inclusion Criteria:\n\n* Male or female participant must be 18 to 55 years of age inclusive, at the time of signing the informed consent\n* Participants who are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, and cardiac monitoring\... | {
"compound": "SAR443820",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT06829212 | Research on Wireless Brain Implant System for General Control of External Devices | NA | RECRUITING | INTERVENTIONAL | false | Shanghai StairMed Technology Co., Ltd. | The clinical trial aims to evaluate the safety and efficacy of the minimally invasive, wireless brain-machine interface system (WRS) in enabling general brain control of external devices, such as a cursor and other assistive technologies, for paralyzed and amputee patients.
WRS integrates a high-throughput, ultra-flex... | [
{
"type": "DEVICE",
"name": "WRS"
}
] | 2025-03 | https://clinicaltrials.gov/study/NCT06829212 | [] | [
{
"facility": "Huashan Hospital Affiliated to Fudan University",
"city": "Shanghai",
"state": "Shanghai Municipality",
"country": "China",
"status": "RECRUITING",
"lat": 31.22222,
"lon": 121.45806
}
] | 021-80510178 | kongcen@stairmed.com | {
"criteria": "Inclusion Criteria:\n\n* Aged 18-80 years (inclusive), any gender.\n* Diagnosed with spinal cord injury, brainstem stroke, amyotrophic lateral sclerosis, or other motor neuron diseases causing partial or complete paralysis, or bilateral upper limb amputation.\n* Diagnosis stable for at least 6 months b... | {
"compound": "unknown",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} |
NCT04744532 | iPSC-based Drug Repurposing for ALS Medicine (iDReAM) Study | PHASE1, PHASE2 | COMPLETED | INTERVENTIONAL | false | Kyoto University | This study consists of a phase 1 part and a phase 2 part.
Phase 1 part:
This is a phase 1, open-label, multicenter, dose escalation study to evaluate the safety and tolerability of bosutinib to determine the maximum tolerated dose(MTD) and a recommended phase 2 dose (RP2D) of bosutinib for treatment of ALS patients. ... | [
{
"type": "DRUG",
"name": "Bosutinib (Phase 1 part)"
},
{
"type": "DRUG",
"name": "Bosutinib (Phase 2 part)"
}
] | 2019-03-19 | https://clinicaltrials.gov/study/NCT04744532 | [
"SRC"
] | [
{
"facility": "Hiroshima University",
"city": "Hiroshima",
"state": "",
"country": "Japan",
"status": "",
"lat": 34.4,
"lon": 132.45
},
{
"facility": "Nara Medical University",
"city": "Kashihara",
"state": "",
"country": "Japan",
"status": "",
"lat": 34.58333... | {
"criteria": "\\[Phase 1 part\\]\n\nInclusion criteria:\n\n1. Evidence of a personally signed and dated informed consent document indicating that the patient has been informed of all pertinent aspects of the study. To be additionaly signed by a delegate signer if the subject is unable to handwrite.\n2. Patients aged... | {
"compound": "Bosutinib",
"targeting_mechanism": "inhibition of the Src/c-Abl pathway",
"targeting_mechanism_pmid": "28539470",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT07006571 | At-home Treatment With Cortico-spinal tDCS for Amyotrophic Lateral Sclerosis | NA | RECRUITING | INTERVENTIONAL | false | University of Trieste | Amyotrophic lateral sclerosis (ALS) is a progressive neurological disease that causes gradual muscle weakness and loss of muscle mass. It affects all muscles that control movement, speech, swallowing, and breathing. Unfortunately, ALS is currently incurable, and treatments are limited. Only two medications, riluzole an... | [
{
"type": "DEVICE",
"name": "Real tDCS"
},
{
"type": "DEVICE",
"name": "Sham tDCS"
}
] | 2025-05-19 | https://clinicaltrials.gov/study/NCT07006571 | [
"corticospinal_tract"
] | [
{
"facility": "Clinica Neurologica, Azienda Sanitaria Universitaria Giuliano Isontina",
"city": "Trieste",
"state": "Trieste",
"country": "Italy",
"status": "RECRUITING",
"lat": 45.64953,
"lon": 13.77678
}
] | +39 0403994282 | benussialberto@gmail.com | {
"criteria": "Inclusion Criteria:\n\n* Male or female patients with a probable, laboratory-supported diagnosis of ALS, or defined ALS according to current clinical criteria\n* Age greater than 18 years\n* Onset of disease ≤ 24 months\n* Disease progression in the last 3 months\n* A score ≥ 2 on the \"respiratory fai... | {
"compound": "unknown",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} |
NCT03076632 | Interactions Between Neurostimulation and Physical Exercise | NA | WITHDRAWN | INTERVENTIONAL | false | Bronx VA Medical Center | * People with cervical spinal cord injury (SCI) and amyotrophic lateral sclerosis (ALS) have reduced connections in the nerve circuits between the brain and the hands. Activating spared nerve circuits is one potential way to improve recovery.
* The investigators are testing different combinations of physical wrist and ... | [
{
"type": "DEVICE",
"name": "Cervical plus transcranial stimulation"
},
{
"type": "DEVICE",
"name": "Cervical stimulation plus hand/wrist exercise"
},
{
"type": "DEVICE",
"name": "Electromyographic (EMG)-triggered (closed-loop) stimulation"
}
] | 2017-04-01 | https://clinicaltrials.gov/study/NCT03076632 | [
"neural_circuit_activation"
] | [] | {
"criteria": "Inclusion Criteria:\n\n1. Age between 21 and 65 years;\n2. Chronic (more than 12 months since injury) incomplete SCI between levels C2-C8 or diagnosis of definite or probable ALS;\n3. Incomplete weakness of left or right hand muscles: score of 2, 3, or 4 (out of 5) on manual muscle testing of finger ex... | {
"compound": "unknown",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT03321487 | Blood-Brain Barrier Opening Using MR-Guided Focused Ultrasound in Patients With Amyotrophic Lateral Sclerosis | NA | COMPLETED | INTERVENTIONAL | false | InSightec | The purpose of this study is to evaluate the safety, tolerability, and feasibility of Blood-Brain Barrier (BBB) opening using transcranial MRI-guided focused ultrasound in conjunction with an intravenous ultrasound contrast agent in patients with Amyotrophic Lateral Sclerosis (ALS). | [
{
"type": "DEVICE",
"name": "Blood-Brain Barrier opening with MRgFUS"
}
] | 2018-04-13 | https://clinicaltrials.gov/study/NCT03321487 | [
"blood_brain_barrier_permeability"
] | [
{
"facility": "Sunnybrook Health Sciences Centre",
"city": "Toronto",
"state": "Ontario",
"country": "Canada",
"status": "",
"lat": 43.70643,
"lon": -79.39864
}
] | {
"criteria": "Inclusion Criteria:\n\n1. Diagnosed with laboratory supported probable, clinically probable or definite ALS according to the World Federation of Neurology Revised El Escorial criteria (Brooks et al. 2000).\n2. Right-hand dominant male or female aged 18 years or older.\n3. Capable of providing informed ... | {
"compound": "MR-guided focused ultrasound (MRgFUS) with ultrasound contrast agent",
"targeting_mechanism": "MR-guided focused ultrasound opens the blood-brain barrier to enable delivery of therapeutic agents to the central nervous system.",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"anima... | ||
NCT06069934 | A Second Intermediate-Size Expanded Access Protocol (EAP) for Pridopidine in People With Amyotrophic Lateral Sclerosis (Pridopidine EAP 2) | Expanded Access | NO_LONGER_AVAILABLE | EXPANDED_ACCESS | true | Prilenia | Protocol PL101-ALS501: This EAP will provide access to pridopidine for up to 200 patients with ALS who are ineligible for clinical trials. | [
{
"type": "DRUG",
"name": "Pridopidine"
}
] | https://clinicaltrials.gov/study/NCT06069934 | [
"D2 dopamine receptor"
] | [
{
"facility": "University of Alabama at Birmingham",
"city": "Birmingham",
"state": "Alabama",
"country": "United States",
"status": "",
"lat": 33.52066,
"lon": -86.80249
},
{
"facility": "Barrow Neurological Institute",
"city": "Phoenix",
"state": "Arizona",
"country... | {
"criteria": "Inclusion Criteria Amyotrophic Lateral Sclerosis (ALS):\n\n* Sporadic or familial ALS.\n* Patient does not qualify for clinical trials of pridopidine or as per site investigator's opinion, and is not medically or geographically suitable for other clinical trials.\n* Capable of providing informed consen... | {
"compound": "Pridopidine",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | |||
NCT02874209 | Noninvasive Assessment of Neuronal Damage by MRI Sodium ( 23Na ) in Amyotrophic Lateral Sclerosis | NA | UNKNOWN | INTERVENTIONAL | false | Assistance Publique Hopitaux De Marseille | Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease affecting the central and peripheral motor neurons, characterized by the rapidity of its evolution (median survival of 3 years). The pathophysiology of the disease is still poorly understood. Neuronal death results from several cellular mechanisms entan... | [
{
"type": "OTHER",
"name": "sodium MRI"
}
] | 2015-09 | https://clinicaltrials.gov/study/NCT02874209 | [
"neuronal_sodium_homeostasis"
] | [
{
"facility": "Assistance Publique Hopitaux de Marseille",
"city": "Masreille",
"state": "",
"country": "France",
"status": "RECRUITING",
"lat": null,
"lon": null
}
] | aude.grapperon@ap-hm.fr | {
"criteria": "Inclusion Criteria:\n\n* Amyotrophic lateral sclerosis patient according to the El Escorial criteria revised Brooks et al. 2000 bulbar or spinal beginning\n\nExclusion Criteria:\n\n* patient or healthy volonteer presenting MRI contre indications to this exam.\n* patient or healthy volonteer presenting ... | {
"compound": "unknown",
"targeting_mechanism": "Sodium MRI measures intracellular sodium accumulation as a biomarker of neuronal dysfunction and neuronal death in motor neurons.",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurposed",
... | |
NCT05959850 | A Double-blind Randomised, Placebo-controlled Clinical Trial to Test Ambroxol Treatment in ALS | PHASE2 | UNKNOWN | INTERVENTIONAL | false | The Florey Institute of Neuroscience and Mental Health | Ambroxol is a simple cough medicine that is predicted to slow ALS disease progression. This study aims to investigate if ambroxol in high doses is effective in treating ALS. This study will be carried out across 5 research sites in Australia (2 NSW, 1 VIC, 1 SA and 1 TAS), where newly diagnosed ALS patients will be ask... | [
{
"type": "DRUG",
"name": "Ambroxol"
},
{
"type": "DRUG",
"name": "Placebo"
}
] | 2023-06-13 | https://clinicaltrials.gov/study/NCT05959850 | [
"Glucocerebrosidase"
] | [
{
"facility": "Brain and Mind Centre",
"city": "Sydney",
"state": "New South Wales",
"country": "Australia",
"status": "RECRUITING",
"lat": -33.86785,
"lon": 151.20732
},
{
"facility": "Concord Repatriation General Hospital",
"city": "Sydney",
"state": "New South Wales",
... | +61 3 9035 6521 | bradley.turner@florey.edu.au | {
"criteria": "Inclusion Criteria:\n\n1. Must have given written informed consent before any study related assessments are performed and must be able to understand purpose of the study, including any possible risks and adverse events.\n2. ALS as diagnosed according to the recently proposed Gold Coast diagnostic crite... | {
"compound": "Ambroxol",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} |
NCT05409508 | Psychological Management by Meditation of Full COnscience in Virtual REality of People With Amyotrophic Lateral Sclerosis: Effects on Cognition, Behavior, Quality of Life and Psychological Well-being | NA | WITHDRAWN | INTERVENTIONAL | false | University Hospital, Angers | Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease that results in progressive paralysis of the muscles involved in voluntary motor skills, speech, swallowing and breathing. It also causes non-motor symptoms including psychological, cognitive and behavioral difficulties that have a negative impact on pa... | [
{
"type": "OTHER",
"name": "mindfulness meditation care"
},
{
"type": "OTHER",
"name": "no mindfulness meditation care"
}
] | 2022-05 | https://clinicaltrials.gov/study/NCT05409508 | [] | [] | {
"criteria": "Inclusion Criteria:\n\n* Majors to inclusion\n* Mother tongue: French\n* Patients for whom ALS of bulbar or spinal form defined according to El Escorial criteria is possible, probable or certain\n* Able to carry out the investigations and interventions provided for in the protocol\n* Signature of infor... | {
"compound": "unknown",
"targeting_mechanism": "Mindfulness meditation delivered in virtual reality targets psychological, cognitive, and behavioral non-motor symptoms of ALS.",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurposed",
"r... | ||
NCT03241784 | Ph1 T-Regulatory Cells in Amyotrophic Lateral Sclerosis | PHASE1 | COMPLETED | INTERVENTIONAL | false | The Methodist Hospital Research Institute | Open-label pilot study to determine the safety and tolerability of autologous CD4+ CD25+ regulatory T cells infusions with concomitant subcutaneous IL-2 injections taken 3 times per week in 3 participants with ALS. | [
{
"type": "BIOLOGICAL",
"name": "Autologous T-regulatory lymphocytes"
},
{
"type": "BIOLOGICAL",
"name": "Interleukin-2"
}
] | 2016-05-16 | https://clinicaltrials.gov/study/NCT03241784 | [
"immune_regulation",
"IL2"
] | [
{
"facility": "Methodist Neurological Institute",
"city": "Houston",
"state": "Texas",
"country": "United States",
"status": "",
"lat": 29.76328,
"lon": -95.36327
}
] | {
"criteria": "Inclusion Criteria:\n\n1. Age 18 years or older.\n2. Sporadic or familial ALS diagnosed as possible, laboratory-supported probable, probable, or definite as defined by revised El Escorial criteria (Appendix 1).\n3. Subjects must not have taken riluzole for at least 30 days, or be on a stable dose of ri... | {
"compound": "Autologous T-regulatory lymphocytes and Interleukin-2",
"targeting_mechanism": "Regulatory T cells exert immunomodulatory and neuroprotective effects to attenuate neuroinflammation in ALS.",
"targeting_mechanism_pmid": "32484719",
"animal_results": "unknown",
"animal_results_pmid": "",
"repur... | ||
NCT04165850 | Open Label Study to Evaluate Ciprofloxacin/Celecoxib Combination in Patients With ALS | PHASE2 | COMPLETED | INTERVENTIONAL | false | NeuroSense Therapeutics Ltd. | This is an open label, off label study, to provide interested ALS patients with Ciprofloxacin/Celecoxib fixed dose combination, while assessing safety and tolerability and routine disease progression measures (ALSFRS-R and Vital Capacity). | [
{
"type": "DRUG",
"name": "Fixed dose combination Ciprofloxacin/Celecoxib"
}
] | 2019-11-25 | https://clinicaltrials.gov/study/NCT04165850 | [
"PTGS2",
"neuroinflammation"
] | [
{
"facility": "Sourasky Medical Center",
"city": "Tel Aviv",
"state": "",
"country": "Israel",
"status": "",
"lat": 32.08088,
"lon": 34.78057
}
] | {
"criteria": "Inclusion Criteria:\n\n1. Able to comprehend and willing to sign an Informed Consent Form (ICF)\n2. Males or females between the ages of 18 and 75 years of age, inclusive\n3. Diagnosis of familial or sporadic ALS (defined as meeting the laboratory-supported probable, probable, or definite criteria for ... | {
"compound": "Ciprofloxacin/Celecoxib fixed dose combination",
"targeting_mechanism": "Combination targeting neuroinflammation through antibiotic and anti-inflammatory mechanisms to address persistent CNS inflammation in ALS.",
"targeting_mechanism_pmid": "28872464",
"animal_results": "unknown",
"animal_resu... | ||
NCT03103815 | Trial of Amivita in Amyotrophic Lateral Sclerosis | NA | UNKNOWN | INTERVENTIONAL | false | Wujin People's Hospital | The primary objectives of this study are to determine the safety and efficacy of Amivita, a compound of amino acids and vitamines in patients with Amyotrophic lateral sclerosis (ALS)ALS. The secondary objectives are to measure quality of life before and during intervention. This is a self-controlled clinical trial. Twe... | [
{
"type": "DRUG",
"name": "Amivita"
}
] | 2017-04-24 | https://clinicaltrials.gov/study/NCT03103815 | [
"oxidative_stress"
] | [
{
"facility": "Wujing People's Hospital",
"city": "Changzhou",
"state": "Jiangsu",
"country": "China",
"status": "RECRUITING",
"lat": 31.77359,
"lon": 119.95401
}
] | 86-519-85579128 | 513325835@qq.com | {
"criteria": "Inclusion Criteria\n\n* Patients must be men or women between the ages of 18 and 70 years\n* Patient is clinical definite or probable ALS by the hospitals listed in the protocol\n* Women who are of child bearing potential must have a negative pregnancy test\n* Willing to comply with the study visits\n*... | {
"compound": "Amivita",
"targeting_mechanism": "Amino acids and vitamins combination addressing oxidative stress and antioxidant system dysfunction in ALS.",
"targeting_mechanism_pmid": "34663413",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid... |
NCT03843710 | 31P-MRS Imaging to Assess the Effects of CNM-Au8 on Impaired Neuronal Redox State in Amyotrophic Lateral Sclerosis (REPAIR-ALS) | PHASE2 | WITHDRAWN | INTERVENTIONAL | false | Clene Nanomedicine | REPAIR-ALS is a single-center open label pilot, sequential group, investigator and patient blinded study to assess the CNS metabolic effects, safety, pharmacokinetics, and pharmacodynamics of CNM-Au8 in patients who have been diagnosed with Amyotrophic Lateral Sclerosis (ALS) within twelve (12) months of Screening. The... | [
{
"type": "DRUG",
"name": "Gold Nanocrystals"
}
] | 2020-03 | https://clinicaltrials.gov/study/NCT03843710 | [
"oxidative_stress",
"neuronal_redox_state"
] | [
{
"facility": "UT Southwestern",
"city": "Dallas",
"state": "Texas",
"country": "United States",
"status": "",
"lat": 32.78306,
"lon": -96.80667
}
] | {
"criteria": "Inclusion Criteria:\n\n1. Able to understand and give written informed consent.\n2. Male or female patients aged 35 years or greater (inclusive) and less than 75 years of age at the time of ALS diagnosis.\n3. Patients with a confirmed ALS diagnosis: \"definite ALS\" or \"probable ALS\" or \"possible\" ... | {
"compound": "Gold Nanocrystals (CNM-Au8)",
"targeting_mechanism": "Gold nanocrystals restore impaired neuronal redox state by targeting NAD+:NADH ratio imbalance and oxidative stress in ALS.",
"targeting_mechanism_pmid": "34198557",
"animal_results": "ASC-Exosomes delayed disease progression in SOD1(G93A) mic... | ||
NCT05039268 | 3K3A-APC for Treatment of Amyotrophic Lateral Sclerosis (ALS) | PHASE2 | COMPLETED | INTERVENTIONAL | false | Macquarie University, Australia | Phase 2 open label trial to investigate the safety and potentially efficacy of 3K3A-APC in patients with Amyotrophic Lateral Sclerosis (ALS). | [
{
"type": "DRUG",
"name": "3K3A-APC Protein"
}
] | 2021-11-25 | https://clinicaltrials.gov/study/NCT05039268 | [
"PAR1",
"neuroprotection"
] | [
{
"facility": "Macquarie University",
"city": "Macquarie Park",
"state": "New South Wales",
"country": "Australia",
"status": "",
"lat": -33.78105,
"lon": 151.12757
}
] | {
"criteria": "Inclusion Criteria:\n\n1. Patients must have clinically definite ALS (Awaji Criteria)\n2. Male or female age 18 years and less than 75 years at time of ALS study\n3. Symptom onset less than 36 months before screening\n4. Diagnosis of ALS less than 24 months before screening\n5. Clinically definite Uppe... | {
"compound": "3K3A-APC Protein",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT04569435 | Study of ANX005 in Adults With Amyotrophic Lateral Sclerosis (ALS) | PHASE2 | COMPLETED | INTERVENTIONAL | false | Annexon, Inc. | This study is a multi-center, open-label study of intravenous (IV) ANX005 in participants with ALS. | [
{
"type": "DRUG",
"name": "ANX005"
}
] | 2021-01-15 | https://clinicaltrials.gov/study/NCT04569435 | [
"C3"
] | [
{
"facility": "Annexon Investigational Site 04",
"city": "Phoenix",
"state": "Arizona",
"country": "United States",
"status": "",
"lat": 33.44838,
"lon": -112.07404
},
{
"facility": "Annexon Investigational Site 01",
"city": "Orange",
"state": "California",
"country":... | {
"criteria": "Key Inclusion Criteria:\n\n* Diagnosis of ALS according to the World Federation of Neurology revised EI Escorial criteria.\n* Onset of weakness within 3 years prior to Day 1 visit.\n* Slow Vital Capacity ≥ 50% of predicted normal adjusted for sex, age, and height (from the sitting position).\n* ALS Fun... | {
"compound": "ANX005",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT00349622 | Clinical Trial Ceftriaxone in Subjects With ALS | PHASE3 | COMPLETED | INTERVENTIONAL | false | Massachusetts General Hospital | The purpose of the study is to evaluate the safety and efficacy of ceftriaxone treatment in amyotrophic lateral sclerosis (ALS). | [
{
"type": "DRUG",
"name": "ceftriaxone"
},
{
"type": "OTHER",
"name": "placebo"
}
] | 2006-07 | https://clinicaltrials.gov/study/NCT00349622 | [
"glutamate_excitotoxicity"
] | [
{
"facility": "Phoenix Neurological Associates",
"city": "Phoenix",
"state": "Arizona",
"country": "United States",
"status": "",
"lat": 33.44838,
"lon": -112.07404
},
{
"facility": "University of California, Davis",
"city": "Davis",
"state": "California",
"country": ... | {
"criteria": "Inclusion Criteria:\n\n* Participants will be people with ALS, at least 18 years of age.\n* Participants must be medically able to undergo the study procedures and have a caregiver or other individual who will be available to help with daily study medication administration.\n* Participants should live ... | {
"compound": "ceftriaxone",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT04579666 | MERIDIAN: A Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults With Amyotrophic Lateral Sclerosis (ALS) | PHASE2 | TERMINATED | INTERVENTIONAL | false | Apellis Pharmaceuticals, Inc. | This is a 24-month, Phase 2, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of pegcetacoplan in subjects with amyotrophic lateral sclerosis (ALS) | [
{
"type": "DRUG",
"name": "Pegcetacoplan (APL-2)"
},
{
"type": "OTHER",
"name": "Placebo"
}
] | 2020-09-30 | https://clinicaltrials.gov/study/NCT04579666 | [
"complement_pathway"
] | [
{
"facility": "Cedars-Sinai Medical Center",
"city": "Los Angeles",
"state": "California",
"country": "United States",
"status": "",
"lat": 34.05223,
"lon": -118.24368
},
{
"facility": "University of Colorado",
"city": "Aurora",
"state": "Colorado",
"country": "United... | {
"criteria": "Inclusion Criteria:\n\n* At least 18 years of age\n* Sporadic ALS diagnosed as definite, probable, or laboratory-supported probable as defined by the revised El Escorial criteria\n* Slow vital capacity (SVC) ≥60% of the predicted value at screening\n* Onset of ALS symptoms within 72 weeks (18 months) p... | {
"compound": "Pegcetacoplan (APL-2)",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT03851302 | Effects of Remote Ischemic Conditioning on Hand Use in Individuals With SCI and ALS | NA | COMPLETED | INTERVENTIONAL | false | Bronx VA Medical Center | Rehabilitation interventions such as physical training and neural stimulation after spinal cord injury (SCI) have been shown to increase neural plasticity. However, both physical training and neural stimulation require a large number of repetitions, and the retention of the intervention effects may be fleeting. In this... | [
{
"type": "OTHER",
"name": "Active Remote Ischemic Conditioning"
},
{
"type": "OTHER",
"name": "Sham Remote Ischemic Conditioning"
},
{
"type": "OTHER",
"name": "Isometric hand exercise"
}
] | 2019-10-28 | https://clinicaltrials.gov/study/NCT03851302 | [] | [
{
"facility": "James J. Peters VA Medical Center",
"city": "The Bronx",
"state": "New York",
"country": "United States",
"status": "",
"lat": 40.84985,
"lon": -73.86641
}
] | {
"criteria": "Able-bodied participants\n\n1. Age between 18 and 75 years;\n2. No known central or peripheral neurological disease or injury.\n\nSCI participants\n\nInclusion Criteria:\n\n1. Age between 18 and 75 years;\n2. Chronic (more than 12 months since injury) motor-incomplete SCI between neurological levels C2... | {
"compound": "Remote Ischemic Conditioning (RIC)",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT07606235 | Transcutaneous Superior Laryngeal Nerve Stimulation to Upregulate Swallowing Frequency and Urge to Swallow in Patients Living With ALS | NA | NOT_YET_RECRUITING | INTERVENTIONAL | false | Nova Southeastern University | Prospective, single-arm pilot study evaluating transcutaneous electrical nerve stimulation of the superior laryngeal nerve (TENS-SLN) in individuals with ALS.
Up to 5 participants with confirmed ALS and bulbar involvement will be enrolled.
Primary outcomes: swallowing frequency and perceived urge to swallow. Particip... | [
{
"type": "OTHER",
"name": "Transcutaneous Superior Laryngeal Nerve Stimulation to Upregulate Swallowing Frequency and Urge to Swallow"
}
] | 2026-06 | https://clinicaltrials.gov/study/NCT07606235 | [] | [] | (954) 262-1271 | rw602@nova.edu | {
"criteria": "Inclusion Criteria:\n\n* Confirmed diagnosis of ALS (El-Escorial Criteria)\n* ALS FRS Bulbar Subscore of ≤ 10 and ≥ 3.\n* Functional Oral Intake scale score ≥ 2\n\nExclusion Criteria:\n\n* A diagnosis of significant cognitive impairment or frontotemporal dementia per the treating neurologist or neurops... | {
"compound": "unknown",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} |
NCT06765564 | Clinical Study of Induced Pluripotent Stem Cells Derived Motor Neuron Precursor Cell Therapy for Amyotrophic Lateral Sclerosis (ALS) | NA | RECRUITING | INTERVENTIONAL | false | Shanghai East Hospital | Amyotrophic lateral sclerosis (ALS) is a severe neurodegenerative disease in the human motor system characterized by the selective involvement of spinal cord anterior horn cells, brainstem motor nuclei, and the corticospinal tract. It predominantly presents as concurrent damage to upper and lower motor neurons.
Induce... | [
{
"type": "DRUG",
"name": "iPSC-MNP"
}
] | 2024-03-13 | https://clinicaltrials.gov/study/NCT06765564 | [
"motor_neuron_regeneration"
] | [
{
"facility": "Shang hai East Hospital",
"city": "Shanghai",
"state": "Shanghai Municipality",
"country": "China",
"status": "RECRUITING",
"lat": 31.22222,
"lon": 121.45806
}
] | {
"criteria": "Inclusion Criteria:\n\n1. Patients themselves or their legal guardians must consent to undergo this treatment protocol and sign the Informed Consent Form (ICF).\n2. Age between 18 and 60 years, inclusive, with no gender restrictions.\n3. Diagnosed with ALS according to the World Federation of Neurology... | {
"compound": "iPSC-MNP (induced pluripotent stem cell-derived motor neuron precursor cells)",
"targeting_mechanism": "Differentiation of induced pluripotent stem cells into motor neuron precursor cells to replace degenerating motor neurons in ALS.",
"targeting_mechanism_pmid": "29789581",
"animal_results": "un... | ||
NCT01759784 | Intraventricular Transplantation of Mesenchymal Stem Cell in Patients With ALS | PHASE1 | WITHDRAWN | INTERVENTIONAL | false | Royan Institute | ALS is a debilitating disease with varied etiology characterized by rapidly progressive weakness, muscle atrophy and fasciculations, muscle spasticity, difficulty speaking (dysarthria), difficulty swallowing (dysphagia), and difficulty breathing (dyspnea). ALS is the most common of the five motor neuron diseases.Riluzo... | [
{
"type": "BIOLOGICAL",
"name": "Intraventricular injection"
}
] | 2014-03 | https://clinicaltrials.gov/study/NCT01759784 | [
"motor_neuron_regeneration"
] | [
{
"facility": "Royan Institute",
"city": "Tehran",
"state": "",
"country": "Iran",
"status": "",
"lat": 35.69439,
"lon": 51.42151
}
] | {
"criteria": "Inclusion Criteria:\n\n* Age:18-65\n* both gender\n* duration of disease\\<2 years\n* FVC\\>40% ALS-FRS\\>26\n\nExclusion Criteria:\n\n* neurological and psychiatric concomitant disease\n* concomitant systemic disease\n* treatment with corticosteroid,Ig,immunosuppressive during 12 months.",
"sex": "A... | {
"compound": "Mesenchymal stem cells (MSC)",
"targeting_mechanism": "Intraventricular transplantation of mesenchymal stem cells to provide neuroprotective support and slow motor neuron degeneration in ALS.",
"targeting_mechanism_pmid": "",
"animal_results": "Intravenous injection of bone marrow-derived mesench... | ||
NCT00925847 | Effect of Lithium Carbonate in Patients With Amyotrophic Lateral Sclerosis | PHASE2 | COMPLETED | INTERVENTIONAL | false | Assistance Publique - Hôpitaux de Paris | The purpose of the study is to determine whether lithium is safe and effective in the treatment of ALS | [
{
"type": "DRUG",
"name": "lithium"
}
] | 2009-06 | https://clinicaltrials.gov/study/NCT00925847 | [
"neuroinflammation"
] | [
{
"facility": "Pitié-Salpêtrière Hospital",
"city": "Paris",
"state": "",
"country": "France",
"status": "",
"lat": 48.85341,
"lon": 2.3488
}
] | {
"criteria": "Inclusion Criteria:\n\n* Diagnosis of clinically possible, clinically probable laboratory-supported, clinically probable or clinically definite ALS (according to WNF EL Escorial diagnostic criteria, revised according to the AIRLIE House Conference 1998)\n* Concomitant standard Riluzole therapy (50mg tw... | {
"compound": "lithium carbonate",
"targeting_mechanism": "Lithium modulates glycogen synthase kinase-3 (GSK-3) and other signaling pathways to reduce neuroinflammation and support motor neuron survival.",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_fr... | ||
NCT06344260 | Neural Stem Cell Treatment for Amyotrophic Lateral Sclerosis (STEMALS) | PHASE2 | RECRUITING | INTERVENTIONAL | false | Casa Sollievo della Sofferenza IRCCS | A Not for Profit Phase II Study to Evaluate Safety, Efficacy and Biomarkers secondary endpoints of Human Neural Stem cell intracerebroventricular transplantation in amyotrophic lateral sclerosis patients: a randomized, placebo controlled, triple blind study.
This is an approximate 24-months study (PHASE B) consisting,... | [
{
"type": "PROCEDURE",
"name": "human Neural Stem Cells (hNSC)"
},
{
"type": "PROCEDURE",
"name": "Saline (Placebo)"
}
] | 2024-01-25 | https://clinicaltrials.gov/study/NCT06344260 | [
"motor_neuron_regeneration"
] | [
{
"facility": "Casa Sollievo Della Sofferenza IRCCS",
"city": "San Giovanni Rotondo",
"state": "Foggia",
"country": "Italy",
"status": "NOT_YET_RECRUITING",
"lat": 41.70643,
"lon": 15.7277
},
{
"facility": "Centro SLA Azienda Ospedaliera Università Maggiore della Carità",
"ci... | +390882835928 | m.carella@operapadrepio.it | {
"criteria": "Inclusion Criteria:\n\n1. Patient provides written informed consent, informed consent signature collection prior to any study procedure (patient has good acceptance and understanding of the informed consent);\n2. Definite, probable diagnosis according to the revised El Escorial criteria;\n3. Age: 18-65... | {
"compound": "human Neural Stem Cells (hNSC)",
"targeting_mechanism": "Intracerebroventricular transplantation of human neural stem cells to provide neuroprotective factors and differentiate into supportive glial and neuronal cell types.",
"targeting_mechanism_pmid": "32043626",
"animal_results": "Preclinical ... |
NCT03793868 | Perampanel Single Ascending Dose Transcranial Magnetic Stimulation Biomarker Study in Amyotrophic Lateral Sclerosis | EARLY_PHASE1 | COMPLETED | INTERVENTIONAL | false | Mayo Clinic | To evaluate if transcranial magnetic stimulation can be used as a biomarker in Amyotrophic Lateral sclerosis (ALS). | [
{
"type": "DRUG",
"name": "Perampanel"
},
{
"type": "OTHER",
"name": "Placebo"
}
] | 2018-12-04 | https://clinicaltrials.gov/study/NCT03793868 | [
"GRIA2"
] | [
{
"facility": "Mayo Clinic",
"city": "Jacksonville",
"state": "Florida",
"country": "United States",
"status": "",
"lat": 30.33218,
"lon": -81.65565
}
] | {
"criteria": "Inclusion Criteria:\n\n1. A probable laboratory supported, probable or definitive ALS diagnosis by revised El Escorial criteria.\n2. Sporadic or familial ALS.\n3. Ages of 18-70.\n4. Agree to use reliable contraception\n5. Randomization will occur after a baseline MT has been established; any subject in... | {
"compound": "Perampanel",
"targeting_mechanism": "AMPA receptor antagonist that blocks glutamate-mediated excitotoxicity in motor neurons.",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT02943850 | CNS10-NPC-GDNF for the Treatment of ALS | PHASE1 | COMPLETED | INTERVENTIONAL | false | Cedars-Sinai Medical Center | The investigator is examining the safety of transplanting cells that have been engineered to produce a growth factor into the spinal cord of patients with Amyotrophic Lateral Sclerosis (ALS). The cells are called neural progenitor cells, which are a type of stem cell that can become several different types of cells in ... | [
{
"type": "BIOLOGICAL",
"name": "Stem cell (HPC) implantation"
},
{
"type": "DEVICE",
"name": "Stereotactic surgical device"
}
] | 2017-04-01 | https://clinicaltrials.gov/study/NCT02943850 | [
"GDNF"
] | [
{
"facility": "Cedars-Sinai Medical Center",
"city": "Los Angeles",
"state": "California",
"country": "United States",
"status": "",
"lat": 34.05223,
"lon": -118.24368
}
] | {
"criteria": "Inclusion Criteria:\n\n1. Confirmed diagnosis of ALS (Lab-supported Probable, Probable or Definite EI Escorial Criteria)\n2. Duration of symptoms ≤ 36 months\n3. Progressive weakness in lower extremities, with EMG supported evidence of denervation in both lower extremities.\n4. Forced Vital Capacity \\... | {
"compound": "CNS10-NPC-GDNF (neural progenitor cells secreting GDNF)",
"targeting_mechanism": "Neural progenitor cells engineered to secrete glial cell line-derived neurotrophic factor (GDNF), a growth factor that provides trophic support to degenerating motor neurons.",
"targeting_mechanism_pmid": "36064599",
... | ||
NCT01897818 | Communication by Brain - Computer Interface in Amyotrophic Lateral Sclerosis:Feasibility Study | NA | UNKNOWN | INTERVENTIONAL | false | Centre Hospitalier Universitaire de Nice | ALS is a severe progressive neurodegenerative disease characterized by degeneration motor neurons leading to death in 3 to 5 years. Gradually in time, the patient deprived of all motor skills as well as the possibility of communication written and oral developing a state close Locked In Syndrome (LIS). The main objecti... | [
{
"type": "DEVICE",
"name": "communication system P300 Speller"
}
] | 2013-07 | https://clinicaltrials.gov/study/NCT01897818 | [] | [
{
"facility": "Hôpital de l'Archet I",
"city": "Nice",
"state": "",
"country": "France",
"status": "RECRUITING",
"lat": 43.70313,
"lon": 7.26608
}
] | desnuelle.c@chu-nice.fr | {
"criteria": "Inclusion Criteria:\n\n* age \\>= 18\n* have a diagnosis of ALS suspected, possible, probable with EMG\n* be able to follow the study process and to comply with the schedule of visits upon entry into the study\n* understand the purpose of the study\n* expressing P300 wave in the conditions of the study... | {
"compound": "Communication system P300 Speller",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurposed",
"repurposed_from_pmid": ""
} | |
NCT07067229 | Non-invasive Brain Stimulation and Exercise Intervention for Patients With Motor Neuron Disease | NA | RECRUITING | INTERVENTIONAL | false | Chulalongkorn University | Motor neuron disease (MND) is a progressive neurological disorder involving degeneration of motor neurons, leading to muscle weakness, speech and swallowing difficulties, and respiratory failure. This study aims to develop a novel treatment approach combining personalized repetitive transcranial magnetic stimulation (r... | [
{
"type": "DEVICE",
"name": "Personalized rTMS"
},
{
"type": "DEVICE",
"name": "Standard rTMS"
},
{
"type": "DEVICE",
"name": "Sham rTMS"
}
] | 2025-08-01 | https://clinicaltrials.gov/study/NCT07067229 | [] | [
{
"facility": "King Chulalongkorn Memorial hospital, The Thai Red Cross Society",
"city": "Bangkok",
"state": "Pathumwan",
"country": "Thailand",
"status": "RECRUITING",
"lat": 13.75398,
"lon": 100.50144
}
] | Thailand: 88-951-9195 | jakkrit.a@chula.ac.th | {
"criteria": "Inclusion Criteria:\n\n* Participants aged between 18 and 80 years\n* Diagnosed with any type of motor neuron disease (MND)\n* Have mild to moderate severity, as assessed by the Sinaki-Mulder scale, with a severity level between 1 and 3\n\nExclusion Criteria:\n\n* History of other neurological disorder... | {
"compound": "Personalized repetitive transcranial magnetic stimulation (rTMS) combined with mixed reality exercise-based games",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurposed",
"repurposed_from... |
NCT00800501 | A Safety and Tolerability Study of Intracerebroventricular Administration of sNN0029 to Patients With Amyotrophic Lateral Sclerosis | PHASE1, PHASE2 | COMPLETED | INTERVENTIONAL | false | Newron Sweden AB | This study is conducted to evaluate the safety and tolerability of the drug product sNN0029, containing the growth factor VEGF165, when administered directly into one of the fluid filled cavities in the brain using an implanted catheter and an implanted SynchroMed® II pump. Patients with Amyotrophic Lateral Sclerosis w... | [
{
"type": "DRUG",
"name": "sNN0029"
},
{
"type": "DRUG",
"name": "Placebo"
}
] | 2008-12 | https://clinicaltrials.gov/study/NCT00800501 | [
"VEGF"
] | [
{
"facility": "University Hospital Leuven, Department of Neurology",
"city": "Leuven",
"state": "",
"country": "Belgium",
"status": "",
"lat": 50.87959,
"lon": 4.70093
}
] | {
"criteria": "Inclusion Criteria:\n\n1. Clinical diagnosis of ALS classified as definite, or probable with or without additional laboratory evidence, according to the revised WFN El Escorial criteria.\n2. Age 18 to 75 years inclusive.\n3. If patients are being treated with riluzole, they must have been on a stable d... | {
"compound": "sNN0029 (containing vascular endothelial growth factor VEGF165)",
"targeting_mechanism": "Vascular endothelial growth factor (VEGF165) delivered intracerebroventricularly to promote neuroprotection and angiogenesis in motor neurons.",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
... | ||
NCT06307301 | Study in ALS With Abatacept & IL-2 | PHASE1 | COMPLETED | INTERVENTIONAL | false | The Methodist Hospital Research Institute | In Amyotrophic Lateral Sclerosis (ALS), the reduction of regulatory T-lymphocyte (Treg) numbers and suppressive function correlates with rapid disease progression. The investigator completed a phase 1 study of infusions of expanded autologous Tregs in combination with subcutaneous IL-2 injections in ALS patients, which... | [
{
"type": "DRUG",
"name": "Abatacept Injection [Orencia] and Proleukin (aldesleukin)"
}
] | 2021-10-28 | https://clinicaltrials.gov/study/NCT06307301 | [
"regulatory_t_lymphocytes"
] | [
{
"facility": "Houston Methodist Research Institute",
"city": "Houston",
"state": "Texas",
"country": "United States",
"status": "",
"lat": 29.76328,
"lon": -95.36327
}
] | {
"criteria": "Inclusion Criteria:\n\nPatients will be eligible for initial enrollment on this study if they meet the following criteria at the time of screening:\n\n1. Provided informed consent and authorized use of protected health information (PHI) in accordance with national and local patient privacy regulations.... | {
"compound": "Abatacept (Orencia) and Proleukin (aldesleukin/IL-2)",
"targeting_mechanism": "Abatacept blocks T-cell costimulation (CD80/CD86-CD28 interaction) while aldesleukin (recombinant IL-2) expands and enhances regulatory T-lymphocyte (Treg) suppressive function to reduce neuroinflammation.",
"targeting_m... | ||
NCT06665165 | AMX0114 in Adult Participants With Amyotrophic Lateral Sclerosis | PHASE1 | RECRUITING | INTERVENTIONAL | false | Amylyx Pharmaceuticals Inc. | This study is a placebo-controlled Phase I study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of the antisense oligonucleotide (ASO) AMX0114 in adult participants with amyotrophic lateral sclerosis (ALS). | [
{
"type": "DRUG",
"name": "AMX0114"
},
{
"type": "OTHER",
"name": "Placebo"
}
] | 2025-04-07 | https://clinicaltrials.gov/study/NCT06665165 | [
"TARDBP"
] | [
{
"facility": "University of California, San Diego",
"city": "La Jolla",
"state": "California",
"country": "United States",
"status": "RECRUITING",
"lat": 32.84727,
"lon": -117.2742
},
{
"facility": "Georgetown University Hospital Pasquerilla Healthcare Center",
"city": "Wash... | 857-320-6200 | clinicaltrials@amylyx.com | {
"criteria": "Inclusion Criteria:\n\n1. Ability to understand the purpose and risks of this study, willingness to comply with the study and to provide informed consent in accordance with local laws and regulations.\n2. Male or female, at least 18 years of age.\n3. Diagnosis of clinically definite or clinically proba... | {
"compound": "AMX0114",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurposed",
"repurposed_from_pmid": ""
} |
NCT06408727 | Intermediate Expanded Access Protocol CNMAu8.EAP04 | Expanded Access | TEMPORARILY_NOT_AVAILABLE | EXPANDED_ACCESS | true | Clene Nanomedicine | An Intermediate Expanded Access Protocol (EAP) with CNM-Au8 for Amyotrophic Lateral Sclerosis for NIH Grant RFA-NS-23-012 | [
{
"type": "DRUG",
"name": "CNM-Au8"
}
] | https://clinicaltrials.gov/study/NCT06408727 | [] | [
{
"facility": "Nova Southeastern University",
"city": "Fort Lauderdale",
"state": "Florida",
"country": "United States",
"status": "",
"lat": 26.12231,
"lon": -80.14338
},
{
"facility": "Northwestern University",
"city": "Chicago",
"state": "Illinois",
"country": "Uni... | {
"criteria": "Inclusion Criteria:\n\n1. Able to understand and give written informed consent.\n2. Male or female participants aged 18 years or greater (inclusive) at the time of informed consent completion.\n3. Participants with a confirmed diagnosis of ALS per Gold Coast criteria as determined by a neurologist spec... | {
"compound": "CNM-Au8",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | |||
NCT07223723 | A Study to Learn More About the Long-Term Safety of Tofersen (Qalsody) in Chinese Participants With SOD-1 Amyotrophic Lateral Sclerosis (ALS) | PHASE4 | ACTIVE_NOT_RECRUITING | INTERVENTIONAL | false | Biogen | In this study, researchers will learn more about the safety of tofersen, also known as Qalsody®. This is a drug available for doctors to prescribe for people with a certain type of amyotrophic lateral sclerosis, also known as ALS. This type is in people who have a mutation in the superoxide dismutase 1 gene, also known... | [
{
"type": "DRUG",
"name": "Tofersen"
}
] | 2025-12-11 | https://clinicaltrials.gov/study/NCT07223723 | [
"SOD1"
] | [
{
"facility": "Peking University Third Hospital",
"city": "Beijing",
"state": "Beijing Municipality",
"country": "China",
"status": "",
"lat": 39.9075,
"lon": 116.39723
}
] | {
"criteria": "Key Inclusion Criteria:\n\n* Age ≥ 18 years at the time of informed consent.\n* Must have diagnosis of SOD1-ALS.\n* If taking riluzole, participant must be on a stable dose for ≥ 30 days prior to Day 1 and expected to remain at that dose until the final study visit.\n* If taking edaravone, participant ... | {
"compound": "Tofersen",
"targeting_mechanism": "Antisense oligonucleotide that reduces SOD1 mRNA and protein levels.",
"targeting_mechanism_pmid": "37975798",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurposed",
"repurposed_from_pmid": ""
} | ||
NCT00983983 | High Fat/High Calorie Trial in Amyotrophic Lateral Sclerosis | PHASE2 | COMPLETED | INTERVENTIONAL | false | Massachusetts General Hospital | The purpose of this study is to determine the safety, tolerability, and preliminary efficacy of long-term use of high fat/high calorie and high calorie diets in people with amyotrophic lateral sclerosis (ALS) (Lou Gehrig's disease). | [
{
"type": "DIETARY_SUPPLEMENT",
"name": "Oxepa"
},
{
"type": "DIETARY_SUPPLEMENT",
"name": "Jevity 1.5"
},
{
"type": "DIETARY_SUPPLEMENT",
"name": "Jevity 1.0"
}
] | 2009-10 | https://clinicaltrials.gov/study/NCT00983983 | [] | [
{
"facility": "Barrow Neurological Institute/St. Joseph's Hospital and Medical Center",
"city": "Phoenix",
"state": "Arizona",
"country": "United States",
"status": "",
"lat": 33.44838,
"lon": -112.07404
},
{
"facility": "University of California at Irvine",
"city": "Irvine",... | {
"criteria": "Inclusion Criteria:\n\n1. Clinical diagnosis of ALS\n2. Male or female subjects aged 18 years or older\n3. Must already be tolerating tube feedings through either a gastrostomy tube (G-tube or PEG) or jejunostomy tube (J-tube)\n4. Must require non-invasive ventilation (BIPAP) for less than 10 hours/day... | {
"compound": "unknown",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT04953286 | Ocular Surface Metabolo-lipidomics in Lateral Amyotrophic Sclerosis | NA | COMPLETED | INTERVENTIONAL | false | University Hospital, Tours | Amyotrophic Lateral Sclerosis (ALS) is the most common neurodegenerative disease affecting the motor neuron. Currently, there is no diagnostic test and no examination that can predict the evolution of this pathology. The search for diagnostic and prognostic biomarkers is therefore essential for a better understanding o... | [
{
"type": "OTHER",
"name": "Measure of visual acuity"
},
{
"type": "OTHER",
"name": "Interferometry"
},
{
"type": "OTHER",
"name": "Samples of basal tears"
},
{
"type": "OTHER",
"name": "Central corneal sensitivity"
},
{
"type": "OTHER",
"name": "Slit lamp exa... | 2021-09-17 | https://clinicaltrials.gov/study/NCT04953286 | [] | [
{
"facility": "Ophthalmology Department, University Hospital of Tours, France",
"city": "Tours",
"state": "",
"country": "France",
"status": "",
"lat": 47.39484,
"lon": 0.70398
},
{
"facility": "Neurology Department, University Hospital of Tours, France",
"city": "Tours",
... | {
"criteria": "Case group selection criteria :\n\nInclusion Criteria:\n\n* Patient with clinically defined or probable primary ALS according to Airlie House criteria(1)\n* Familial or sporadic form\n* ≥18 years of age\n* Patient affiliated with a social security plan\n* Informed consent signed by the patient\n\nExclu... | {
"compound": "unknown",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT06977451 | Personalized Antisense Oligonucleotide for a Single Participant With CHCHD10 ALS | PHASE1, PHASE2 | ACTIVE_NOT_RECRUITING | INTERVENTIONAL | false | n-Lorem Foundation | This research project entails delivery of a personalized antisense oligonucleotide (ASO) drug designed for a single participant with amyotrophic lateral sclerosis (ALS) due to a pathogenic variant in CHCHD10 | [
{
"type": "DRUG",
"name": "nL-CHCHD-001"
}
] | 2024-06-24 | https://clinicaltrials.gov/study/NCT06977451 | [
"CHCHD10"
] | [
{
"facility": "Columbia University, Irving Medical Center",
"city": "New York",
"state": "New York",
"country": "United States",
"status": "",
"lat": 40.71427,
"lon": -74.00597
}
] | {
"criteria": "Inclusion Criteria:\n\n* Informed consent/assent provided by the participant (when appropriate), and/or participant's parent(s) or legally authorized representative(s).\n* Ability to travel to the study stie and adhere to study-related follow-up examinations and/or procedures and provide access to part... | {
"compound": "nL-CHCHD-001",
"targeting_mechanism": "Personalized antisense oligonucleotide targeting CHCHD10 to suppress pathogenic variants in this gene associated with ALS",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurposed",
"re... | ||
NCT01583088 | Early Stage Amyotrophic Lateral Sclerosis Phrenic Stimulation | PHASE3 | TERMINATED | INTERVENTIONAL | false | Assistance Publique - Hôpitaux de Paris | ALS is is characterized by a progressive degeneration of motor neurons, leading to progressive weakness of muscles, including respiratory muscles, the diaphragm. Although specific therapy is lacking, correct respiratory therapy improves quality of life and increases survival. Substituting the failing respiratory muscle... | [
{
"type": "DEVICE",
"name": "phenique nerve stimulation NeurX™ (Synapse Biomedical)"
},
{
"type": "DEVICE",
"name": "sham phrenic nerve stimulation"
}
] | 2012-09 | https://clinicaltrials.gov/study/NCT01583088 | [
"respiratory_function"
] | [
{
"facility": "APHP, GH Pitié Salpêtrière",
"city": "Paris",
"state": "",
"country": "France",
"status": "",
"lat": 48.85341,
"lon": 2.3488
}
] | {
"criteria": "Inclusion Criteria:\n\n* Diagnosis is laboratory-supported probable, probable, or definite according to the World Federation of Neurology El Escorial criteria\n* Forced Vital Capacity (FVC) from 80 - 60% of predicted values at enrollment\n* Bilateral phrenic nerve function acceptable as demonstrated by... | {
"compound": "NeurX™ phrenic nerve stimulator",
"targeting_mechanism": "Intradiaphragmatic phrenic nerve stimulation to directly activate the diaphragm and maintain respiratory function",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurpo... | ||
NCT03659422 | Dietary Approach to Improving Quality of Life in Amyotrophic Lateral Sclerosis | NA | WITHDRAWN | INTERVENTIONAL | false | Terry L. Wahls | We have had reports of an individual who utilized a modified Paleolithic diet and vitamin/ supplement program as part of his approach to managing ALS related symptoms. This individual has experienced stability in his ALS functional rating score and stable to improving strength over an 18 month period. There are also an... | [
{
"type": "OTHER",
"name": "Modified Paleolithic diet"
}
] | 2019-07-01 | https://clinicaltrials.gov/study/NCT03659422 | [] | [] | {
"criteria": "Inclusion Criteria:\n\n1. Diagnosis of clinically possible, clinically probable (with or without laboratory support), or clinically definite ALS (using the revised El Escorial Criteria)\n2. Ability to prepare, or have prepared for them, home-cooked meals\n3. Age between 18 and 80 years\n4. Followed by ... | {
"compound": "Modified Paleolithic diet",
"targeting_mechanism": "Dietary intervention aimed at addressing metabolic abnormalities and nutritional deficits in ALS",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurposed",
"repurposed_fro... | ||
NCT05508074 | Treatment Combining Riluzole and IFB-088 in Bulbar Amyotrophic Lateral Sclerosis (TRIALS Protocol) | PHASE2 | COMPLETED | INTERVENTIONAL | false | InFlectis BioScience | Prospective, international, randomised, double-blind, placebo controlled, multicentre, parallel group study. Patients will be randomised in a 2:1 allocation ratio to receive either IFB-088 + riluzole 100 mg or placebo + riluzole 100 mg. This clinical trial is an exploratory study, designed to show a signal of efficacy ... | [
{
"type": "DRUG",
"name": "IFB-088 50mg/day"
},
{
"type": "DRUG",
"name": "Placebo"
},
{
"type": "DRUG",
"name": "Riluzole 100mg/day"
}
] | 2022-12-02 | https://clinicaltrials.gov/study/NCT05508074 | [
"riluzole",
"ifb_088"
] | [
{
"facility": "Hôpital Neurologique Pierre Wertheimer",
"city": "Bron",
"state": "",
"country": "France",
"status": "",
"lat": 45.73865,
"lon": 4.91303
},
{
"facility": "APHM Hôpital La Timone Adultes SCE Maladies Neuromusculaires / SLA",
"city": "Marseille",
"state": "",... | {
"criteria": "Inclusion Criteria:\n\n1. Diagnosis of probable or definite ALS according to the revised El Escorial criteria \\[29\\], with bulbar onset of disease, familial or sporadic form,\n2. Onset of symptoms ≤ 18 months prior to screening, as reported by the patient,\n3. Adult males or females, aged at least 18... | {
"compound": "IFB-088",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT07571174 | A Substudy of LY4256984 in Participants With Sporadic Amyotrophic Lateral Sclerosis | PHASE1 | RECRUITING | INTERVENTIONAL | false | Eli Lilly and Company | The main purpose of this study is to assess the long-term safety and tolerability of LY4256984 in participants with Amyotrophic Lateral Sclerosis (ALS). This study is a long-term extension of study J6I-MC-OWAA (NCT07100119) and is part of the OLMP (NCT07571200) master protocol that will last approximately 96 weeks. | [
{
"type": "DRUG",
"name": "LY4256984"
}
] | 2026-05-14 | https://clinicaltrials.gov/study/NCT07571174 | [
"ly4256984"
] | [
{
"facility": "UZ Leuven",
"city": "Leuven",
"state": "",
"country": "Belgium",
"status": "NOT_YET_RECRUITING",
"lat": 50.87959,
"lon": 4.70093
},
{
"facility": "University Hospital - London Health Sciences Centre",
"city": "London",
"state": "",
"country": "Canada",
... | 1-317-615-4559 | LillyTrials@Lilly.com | {
"criteria": "Participants must meet eligibility criteria in the \\[L0U-MC-OLMP\\] screening protocol before entry into the treatment study.\n\nInclusion Criteria:\n\n* Have completed the main treatment period/phase as well as any off-treatment period/phase of Study OWAA, the parent study for this ISA.\n\nExclusion ... | {
"compound": "LY4256984",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} |
NCT01959373 | Dysfunctions and Plasticity Mechanisms of Motor System Assessed by Cortico-cortical and Cortico-muscular Coherence Analysis in Amyotrophic Lateral Sclerosis | NA | SUSPENDED | INTERVENTIONAL | false | Assistance Publique Hopitaux De Marseille | Amyotrophic lateral sclerosis (ALS) is characterized clinically by abnormalities of both upper motor neurons (UMN) and lower motor neurons (LMN). The presence of UMN signs is not always easy to establish. The only technique used in routine to assess the corticospinal dysfunctions is based on transcranial magnetic stimu... | [
{
"type": "PROCEDURE",
"name": "electroencephalograms (EEG)"
},
{
"type": "PROCEDURE",
"name": "electro-myography (EMG)"
}
] | 2013-10 | https://clinicaltrials.gov/study/NCT01959373 | [] | [
{
"facility": "Assistance Publique Hopitaux de Marseille",
"city": "Marseille",
"state": "",
"country": "France",
"status": "",
"lat": 43.29695,
"lon": 5.38107
}
] | {
"criteria": "Inclusion Criteria:\n\n* Patient female or male, more than 18 years,\n* Patien with a diagnosis of amyotrophic lateral sclerosis according to the El Escorial criteria of Brooks et al. 1994\n* Patient , the beginning of the SLA date less than 12 months,\n* Patient not having a familial form of ALS,\n* P... | {
"compound": "unknown",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurposed",
"repurposed_from_pmid": ""
} | ||
NCT00833820 | Repetitive Transcranial Magnetic Stimulation (rTMS) in Amyotrophic Lateral Sclerosis | PHASE2, PHASE3 | COMPLETED | INTERVENTIONAL | false | Catholic University of the Sacred Heart | The investigators' preliminary studies demonstrated that repetitive transcranial magnetic stimulation (rTMS) of the brain may determine a slight slowing in the rate of disease progression in ALS patients (Di Lazzaro et al 2004, 2006). The aim of this study is to investigate whether rTMS of the motor cortex performed ov... | [
{
"type": "PROCEDURE",
"name": "Real rTMS of the brain"
},
{
"type": "PROCEDURE",
"name": "Sham rTMS of the brain"
}
] | 2007-05 | https://clinicaltrials.gov/study/NCT00833820 | [
"motor_cortex_plasticity"
] | [
{
"facility": "Institute of neurology Università Cattolica",
"city": "Rome",
"state": "",
"country": "Italy",
"status": "",
"lat": 41.89193,
"lon": 12.51133
}
] | {
"criteria": "Inclusion Criteria:\n\n* Eligible patients should have a diagnosis of definite ALS according to the El Escorial revised criteria with clear clinical upper and lower motor neuron signs.\n\nExclusion Criteria:\n\n* Contraindications to transcranial magnetic stimulation:\n\n * Tracheostomy\n * Pace-make... | {
"compound": "repetitive transcranial magnetic stimulation (rTMS)",
"targeting_mechanism": "Non-invasive neuromodulation of motor cortex to slow disease progression",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurposed",
"repurposed_f... | ||
NCT03452618 | Predictive Factors for the Diagnosis of Early Noninvasive Ventilation Equipment | NA | UNKNOWN | INTERVENTIONAL | false | University Hospital, Toulouse | To compensate for insufficiency of diagnostic tools, the present study propose to look for the predictive factors of an early fitting by noninvasive ventilation. | [
{
"type": "DIAGNOSTIC_TEST",
"name": "diagnosis variables"
}
] | 2017-12-14 | https://clinicaltrials.gov/study/NCT03452618 | [] | [
{
"facility": "University Hospital Toulouse",
"city": "Toulouse",
"state": "",
"country": "France",
"status": "RECRUITING",
"lat": 43.60426,
"lon": 1.44367
}
] | 5 67 77 16 91 | dupuis.m@chu-toulouse.fr | {
"criteria": "Inclusion Criteria:\n\n* diagnosis of amyotrophic lateral sclerosis just performed,\n* Patient who do not have the criteria for fitting by NIV and who have a Vital capacity ≥ 70% of theoretical values\n\nExclusion Criteria:\n\n* Patient under court bail/ guardianship\n* Lack of consent for participatio... | {
"compound": "unknown",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurposed",
"repurposed_from_pmid": ""
} |
NCT06819124 | Examining Interactions Between PALS and Caregivers | NA | RECRUITING | INTERVENTIONAL | false | Penn State University | The goal of this clinical trial is to learn about the effect of communicative interaction on verbal communication in people with amyotrophic lateral sclerosis (ALS) and their caregivers.
The question is, What are the effects of communicative interaction on verbal communication in people with ALS when they interact wit... | [
{
"type": "BEHAVIORAL",
"name": "Structured Communicative Interaction"
},
{
"type": "BEHAVIORAL",
"name": "Unstructured communicative interaction"
}
] | 2025-01-22 | https://clinicaltrials.gov/study/NCT06819124 | [] | [
{
"facility": "Speech Core, Pennsylvania State University",
"city": "University Park",
"state": "Pennsylvania",
"country": "United States",
"status": "RECRUITING",
"lat": 40.80201,
"lon": -77.85639
}
] | 814-867-3373 | ajo150@psu.edu | {
"criteria": "Inclusion Criteria:\n\nSpeakers with amyotrophic lateral sclerosis (ALS) (PALS-people with ALS)\n\n* diagnosis of ALS following the revised EL Escorial criteria\n* no history of other neurological conditions (e.g., stroke)\n* no cognitive impairment assessed by Telephone Montreal Cognitive Assessment (... | {
"compound": "unknown",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurposed",
"repurposed_from_pmid": ""
} |
NCT04494256 | A Study to Assess the Safety, Tolerability, and Effect on Disease Progression of BIIB105 in Participants With Amyotrophic Lateral Sclerosis (ALS) and Participants With the ALS Ataxin-2 (ATXN2) Genetic Mutation | PHASE1, PHASE2 | TERMINATED | INTERVENTIONAL | false | Biogen | The ALSpire Study is a clinical trial evaluating the investigational drug BIIB105 in adults living with amyotrophic lateral sclerosis (ALS).
The ALSpire Study consists of two parts:
* Part 1: 6-month placebo-controlled study. During Part 1, participants are randomly assigned to receive either BIIB105 or placebo in a ... | [
{
"type": "DRUG",
"name": "BIIB105"
},
{
"type": "DRUG",
"name": "Placebo"
}
] | 2020-09-28 | https://clinicaltrials.gov/study/NCT04494256 | [
"ATXN2",
"biib105"
] | [
{
"facility": "Barrow Neurological Institute",
"city": "Phoenix",
"state": "Arizona",
"country": "United States",
"status": "",
"lat": 33.44838,
"lon": -112.07404
},
{
"facility": "University of California San Diego Medical Center",
"city": "La Jolla",
"state": "Californi... | {
"criteria": "Key Inclusion Criteria:\n\nPart 1:\n\n* Ability of the participant to understand the purpose and risks of the study and indicate informed consent, and the ability of the participant or the participant's legally authorized representative, to provide signed and dated informed consent and authorization to... | {
"compound": "BIIB105",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT06527222 | A Study of Ranolazine in ALS | PHASE2 | RECRUITING | INTERVENTIONAL | false | Swathy Chandrashekhar, MBBS | The purpose of this study is to evaluate safety, effect on cramps, function and quality of life of ranolazine versus placebo for the treatment of ALS. | [
{
"type": "DRUG",
"name": "Ranolazine"
},
{
"type": "DRUG",
"name": "Ranolazine"
},
{
"type": "DRUG",
"name": "Placebo"
}
] | 2025-04-29 | https://clinicaltrials.gov/study/NCT06527222 | [
"muscle_cramps"
] | [
{
"facility": "University of California, San Francisco",
"city": "San Francisco",
"state": "California",
"country": "United States",
"status": "RECRUITING",
"lat": 37.77493,
"lon": -122.41942
},
{
"facility": "Mayo Clinic Florida",
"city": "Jacksonville",
"state": "Florid... | 913-945-9932 | Kjennens2@kumc.edu | {
"criteria": "Inclusion Criteria:\n\n* 18 years or older\n* Diagnosed with clinically definite, possible, probably, or lab-supported probable ALS per revised El Escorial criteria\n* Breathing assessment called forced vital capacity (FVC) greater than or equal to 50%.\n* Able to swallow pills at the start of the stud... | {
"compound": "Ranolazine",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} |
NCT05983211 | Quantitative and Repetitive TMS in ALS - Recruiting for Stage 2 | NA | RECRUITING | INTERVENTIONAL | false | Sunnybrook Health Sciences Centre | Stage 1 \[Enrolment closed\]:
The goal of this open-label pilot clinical trial is to evaluate the safety and feasibility of accelerated, repetitive transcranial magnetic stimulation (rTMS) using continuous theta-burst stimulation (cTBS) in patients with ALS.
Stage 2 \[CURRENTLY ENROLLING\]:
The goal of this open-lab... | [
{
"type": "DEVICE",
"name": "Repetitive Transcranial Magnetic Stimulation"
}
] | 2024-05-01 | https://clinicaltrials.gov/study/NCT05983211 | [
"motor_cortex_excitability"
] | [
{
"facility": "Sunnybrook Health Sciences Centre",
"city": "Toronto",
"state": "Ontario",
"country": "Canada",
"status": "RECRUITING",
"lat": 43.70643,
"lon": -79.39864
}
] | (416) 480-6100 | alsresearch@sunnybrook.ca | {
"criteria": "Inclusion Criteria:\n\n* Diagnosis with ALS as per the 2020 Gold Coast Criteria;\n* Age ≥ 18 years;\n* Able to provide informed consent to study procedures and treatments;\n* Patients are allowed to start or continue the standard of care treatments for ALS. Presently these include oral riluzole, and or... | {
"compound": "unknown",
"targeting_mechanism": "Repetitive transcranial magnetic stimulation using continuous theta-burst stimulation (cTBS) to modulate motor cortex activity in ALS.",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurposed... |
NCT02058732 | Therapeutic Imaging Biomarkers for Amyotrophic Lateral Sclerosis | NA | TERMINATED | INTERVENTIONAL | false | University of Michigan | Study the cervical spinal cord and brain over time to assess changes and differences in subjects with amyotrophic lateral sclerosis. | [
{
"type": "OTHER",
"name": "MRI"
}
] | 2013-11 | https://clinicaltrials.gov/study/NCT02058732 | [] | [
{
"facility": "University of Michigan Hospital",
"city": "Ann Arbor",
"state": "Michigan",
"country": "United States",
"status": "",
"lat": 42.27756,
"lon": -83.74088
}
] | {
"criteria": "Inclusion Criteria:\n\n1. 18 years of age or older\n2. Subjects with amyotrophic lateral sclerosis -\n\nExclusion Criteria:\n\n1. Do not have opportunistic central nervous system infection\n2. Do not have a history of head injury\n3. Do not have cerebrovascular disease\n4. Do not have a contraindicatio... | {
"compound": "unknown",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurposed",
"repurposed_from_pmid": ""
} | ||
NCT04220021 | Safety and Therapeutic Potential of the FDA-approved Drug Metformin for C9orf72 ALS/FTD | PHASE2 | ACTIVE_NOT_RECRUITING | INTERVENTIONAL | false | University of Florida | The primary objective is to assess the safety and tolerability of Metformin in subjects with C9orf72 amyotrophic lateral sclerosis administered for 24 weeks. The overall objective is to determine if Metformin is safe in C9orf72 ALS patients and is a potentially viable therapeutic treatment for C9-ALS that reduces repea... | [
{
"type": "DRUG",
"name": "Metformin"
}
] | 2020-01-10 | https://clinicaltrials.gov/study/NCT04220021 | [
"C9orf72"
] | [
{
"facility": "UF Health at the University of Florida",
"city": "Gainesville",
"state": "Florida",
"country": "United States",
"status": "",
"lat": 29.65163,
"lon": -82.32483
}
] | {
"criteria": "Inclusion Criteria:\n\n* Subjects have a diagnosis of probable or definite ALS in accordance with the Revisited El-Escorial Criteria.\n* Subjects have a likely diagnosis of chromosome 9 open reading frame 72 (C9orf72) positive ALS/FTD.\n* Subjects must be currently on an oral diet and able to take food... | {
"compound": "Metformin",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT02794857 | Safety and Efficacy Study of NP001 in Patients With Amyotrophic Lateral Sclerosis (ALS) and Systemic Inflammation | PHASE2 | COMPLETED | INTERVENTIONAL | false | Neuraltus Pharmaceuticals, Inc. | This study evaluates NP001 in patients with amyotrophic lateral sclerosis (ALS) and evidence of systemic inflammation. Half of participants will receive NP001 and the other half will receive placebo. | [
{
"type": "DRUG",
"name": "NP001"
},
{
"type": "DRUG",
"name": "Placebo"
}
] | 2016-08-29 | https://clinicaltrials.gov/study/NCT02794857 | [
"neuroinflammation"
] | [
{
"facility": "St. Joseph's Hospital and Medical Center - Barrow Neurology Clinics",
"city": "Phoenix",
"state": "Arizona",
"country": "United States",
"status": "",
"lat": 33.44838,
"lon": -112.07404
},
{
"facility": "Mayo Clinic Arizona",
"city": "Scottsdale",
"state": ... | {
"criteria": "Key Inclusion Criteria:\n\n* Diagnosis of clinically possible, clinically probable (with or without laboratory support), or clinically definite ALS (using the revised El Escorial Criteria)\n* Forced vital capacity greater than or equal to 65% of that predicted for age and height\n* Onset of ALS-related... | {
"compound": "NP001",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT03019419 | Perampanel for Sporadic Amyotrophic Lateral Sclerosis (ALS) | PHASE2 | COMPLETED | INTERVENTIONAL | false | Tokyo Medical University | To investigate the safety and the efficacy of perampanel in patients with sporadic amyotrophic lateral sclerosis | [
{
"type": "DRUG",
"name": "Perampanel"
},
{
"type": "DRUG",
"name": "placebo"
}
] | 2017-04-24 | https://clinicaltrials.gov/study/NCT03019419 | [
"glutamate_excitotoxicity"
] | [
{
"facility": "Kitasato University East Hospital",
"city": "Kanagawa",
"state": "",
"country": "Japan",
"status": "",
"lat": 37.58333,
"lon": 139.91667
},
{
"facility": "Kumamoto Saishunso National Hospital",
"city": "Kumamoto",
"state": "",
"country": "Japan",
"s... | {
"criteria": "\\[Eligibility Criteria for Interim Registration\\]\n\n* Patients who are able to submit written informed consent. If patients are duly capable of study consent but are unable to sign by themselves due to aggravation of disease condition, written informed consent can be obtained from a legally authoriz... | {
"compound": "Perampanel",
"targeting_mechanism": "AMPA receptor antagonist that blocks glutamate excitotoxicity.",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT02306109 | Effect of Motor Rehabilitation Treatment on Amyotrophic Lateral Sclerosis (ALS) | NA | COMPLETED | INTERVENTIONAL | false | Azienda Unita' Sanitaria Locale Di Modena | ErmoSLA is a multicentric, randomized, controlled trial to compare effects of an "intensive" or "standard" motor rehabilitation treatment on motor disability in people with ALS | [
{
"type": "PROCEDURE",
"name": "Standard motor rehabilitation treatment"
},
{
"type": "PROCEDURE",
"name": "Intensive motor rehabilitation treatment"
}
] | 2015-01 | https://clinicaltrials.gov/study/NCT02306109 | [] | [
{
"facility": "Department of Neuroscience, S. Anna Hospital",
"city": "Ferrara",
"state": "",
"country": "Italy",
"status": "",
"lat": 44.83804,
"lon": 11.62057
},
{
"facility": "Department of Neuroscience, S.Agostino-Estense Hospital",
"city": "Modena",
"state": "",
... | {
"criteria": "Inclusion Criteria:\n\n* Diagnosis of possible, probable or definite ALS according to the Revised El Escorial Criteria\n* Time from diagnosis \\<18 months at screening.\n* Forced vital capacity (FVC)\\> 50% at screening\n* Written informed consent\n\nPatients will be required to take the full dose of R... | {
"compound": "unknown",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT02525471 | A Pilot Study of RNS60 in Amyotrophic Lateral Sclerosis (ALS) | PHASE1 | COMPLETED | INTERVENTIONAL | false | Sabrina Paganoni, M.D. | The purpose of this study is to determine the safety and tolerability of RNS60 in patients with Amyotrophic lateral sclerosis (ALS). Investigators will also measure the impact of RNS60 on several markers of neuro-inflammation, measured by blood biomarkers and positron emission tomography (PET) imaging. | [
{
"type": "DRUG",
"name": "RNS60"
}
] | 2015-10 | https://clinicaltrials.gov/study/NCT02525471 | [
"neuroinflammation"
] | [
{
"facility": "Massachusetts General Hospital",
"city": "Boston",
"state": "Massachusetts",
"country": "United States",
"status": "",
"lat": 42.35843,
"lon": -71.05977
}
] | {
"criteria": "Inclusion Criteria:\n\n* Amyotrophic Lateral Sclerosis (ALS) volunteers must be diagnosed as having possible, probable, probable-laboratory supported, or definite ALS, either sporadic or familial according to modified El Escorial criteria.\n* Age 18-80, able to provide informed consent, and comply with... | {
"compound": "RNS60",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT01884571 | Immunosuppression in Amyotrophic Lateral Sclerosis (ALS) | PHASE2 | COMPLETED | INTERVENTIONAL | false | Emory University | This is a multicenter, 15-month study evaluating the effect of immunosuppression treatment on the rate of change on the ALS Functional Rating Scale (Revised) (ALSFRS-R) score in up to 33 subjects with Amyotrophic Lateral Sclerosis (ALS). | [
{
"type": "DRUG",
"name": "Basiliximab"
},
{
"type": "DRUG",
"name": "Methylprednisolone"
},
{
"type": "DRUG",
"name": "Prednisone"
},
{
"type": "DRUG",
"name": "Tacrolimus"
},
{
"type": "DRUG",
"name": "Mycophenolate mofetil"
}
] | 2013-10 | https://clinicaltrials.gov/study/NCT01884571 | [
"immune_system"
] | [
{
"facility": "Emory University",
"city": "Atlanta",
"state": "Georgia",
"country": "United States",
"status": "",
"lat": 33.749,
"lon": -84.38798
},
{
"facility": "Massachusetts General Hospital",
"city": "Boston",
"state": "Massachusetts",
"country": "United States"... | {
"criteria": "Inclusion Criteria for participants with symptom onset within the past 24 months:\n\n* Male or female patients 18-65 years of age.\n* ALS diagnosed as possible, laboratory-supported probable, probable, or definite as defined by revised El Escorial Criteria.\n* Symptom onset ≤ 24 months from screening v... | {
"compound": "Basiliximab, Methylprednisolone, Prednisone, Tacrolimus, Mycophenolate mofetil",
"targeting_mechanism": "Immunosuppression therapy targeting immune-mediated motor neuron degeneration.",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": ... | ||
NCT07047209 | Trial of Oral Digoxin in Individuals With Amyotrophic Lateral Sclerosis (ALS) | PHASE2 | COMPLETED | INTERVENTIONAL | false | Massachusetts General Hospital | This clinical trial is being conducted to learn about safety and tolerability of digoxin in ALS individuals. Additionally, this trial aims to better understand if digoxin has an effect on slowing neurodegeneration in ALS. | [
{
"type": "DRUG",
"name": "Digoxin"
}
] | 2025-05-27 | https://clinicaltrials.gov/study/NCT07047209 | [
"Na/K-ATPase"
] | [
{
"facility": "Nova Southeastern University",
"city": "Davie",
"state": "Florida",
"country": "United States",
"status": "",
"lat": 26.06287,
"lon": -80.2331
},
{
"facility": "Northwestern Universsity",
"city": "Chicago",
"state": "Illinois",
"country": "United States... | {
"criteria": "Inclusion Criteria:\n\n1. Ability to provide written informed consent.\n2. Adults \\>18 years of age with a diagnosis of symptomatic ALS as determined by an ALS neurologist, and meets either the revised El Escorial Criteria (clinically possible, probable, probable lab-supported, or definite) or the Gol... | {
"compound": "Digoxin",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT07726563 | Plasmapheresis in Amyotrophic Lateral Sclerosis With Autoantibody Against NRIP 2 (PALADIN2) | NA | RECRUITING | INTERVENTIONAL | false | National Taiwan University Hospital | 10-20% of patients with ALS have anti-NRIP autoantibody and the titer of anti-NRIP autoantibody is correlated with motor functional decline and mortality in ALS. The PALADIN2 clinical trial is a single arm study, which intends to enroll 20 ALS patients having anti-NRIP autoantibody in plasma. Patients will receive 3 co... | [
{
"type": "DEVICE",
"name": "plasmapheresis"
}
] | 2026-05-19 | https://clinicaltrials.gov/study/NCT07726563 | [
"NRIP1"
] | [
{
"facility": "National Taiwan University Hospital",
"city": "Taipei City",
"state": "Taipei",
"country": "Taiwan",
"status": "RECRUITING",
"lat": null,
"lon": null
}
] | +886972651560 | milikai@ntuh.gov.tw | {
"criteria": "Inclusion Criteria:\n\n* ALS patients above 20-year-old who have anti-NRIP autoantibody in plasma\n* Agree to receive plasmapheresis treatment\n* Agree to participate in the study and receive serial examinations\n\nExclusion Criteria:\n\n* Under permanent ventilator support\n* Cannot receive plasmapher... | {
"compound": "plasmapheresis",
"targeting_mechanism": "Removal of anti-NRIP autoantibodies from plasma to reduce their circulating concentration and associated motor neuron degeneration.",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurp... |
NCT02851914 | SSRIs vs. TCAs for Depression in ALS Patients | EARLY_PHASE1 | COMPLETED | INTERVENTIONAL | false | St. Louis University | Depression is seen in 9-11% of ALS patients and adequate and proper treatment is needed. In this study, ALS patients will be screened for depression using self-reported multiple choice questionnaire. Patients who fulfill the criteria for depression based on this screening tool will be evaluated by psychiatrist before i... | [
{
"type": "DRUG",
"name": "Tricyclic Antidepressants (\"TCA\")"
},
{
"type": "DRUG",
"name": "Selective Serotonin Uptake Inhibitors (\"SSRI\")"
}
] | 2015-07-21 | https://clinicaltrials.gov/study/NCT02851914 | [
"serotonin_reuptake"
] | [
{
"facility": "Monteleone Hall, Saint Louis University, 1438 South Grand Blvd.",
"city": "St Louis",
"state": "Missouri",
"country": "United States",
"status": "",
"lat": 38.62727,
"lon": -90.19789
}
] | {
"criteria": "Inclusion Criteria:\n\n* Documented diagnosis of definite or probable ALS\n* Informed and written consent for enrollment in study\n* Gender: both male and female\n* Age: 25-80 years\n* BDI score 19 or above\n* Depression diagnosis by mental health provider\n\nExclusion Criteria:\n\n* History of psychot... | {
"compound": "Tricyclic Antidepressants and Selective Serotonin Uptake Inhibitors",
"targeting_mechanism": "Modulation of serotonin and norepinephrine reuptake to treat depression in ALS patients.",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "... | ||
NCT01424163 | Dexpramipexole Japanese PK Study | PHASE1 | COMPLETED | INTERVENTIONAL | false | Knopp Biosciences | This is a single and multiple dose, open-label study to evaluate the pharmacokinetics (PK), safety, and tolerability of dexpramipexole administered orally to adult Japanese and Caucasian healthy subjects. | [
{
"type": "DRUG",
"name": "Single dose reduced"
},
{
"type": "DRUG",
"name": "Single dose standard"
},
{
"type": "DRUG",
"name": "Multiple Dose"
},
{
"type": "DRUG",
"name": "Multiple Dose"
}
] | 2011-08 | https://clinicaltrials.gov/study/NCT01424163 | [
"dexpramipexole"
] | [
{
"facility": "Research Site",
"city": "London",
"state": "",
"country": "United Kingdom",
"status": "",
"lat": 51.50853,
"lon": -0.12574
}
] | {
"criteria": "Inclusion Criteria:\n\n* Subjects who are able and willing to give written informed consent.\n* Adult Japanese and Caucasian males/females aged 18 to 60 years inclusive and between 18 and 30 kg/m2 body mass index (BMI), inclusive.\n* Male and female subjects will be enrolled on the study. Male subjects... | {
"compound": "dexpramipexole",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT05357950 | A Phase IIb, Multi-Center, Multinational, Double-Blind, Placebo-Controlled Study, With an Open Label Extension, to Evaluate Safety, Tolerability and Efficacy of PrimeC in Subjects With ALS | PHASE2 | COMPLETED | INTERVENTIONAL | false | NeuroSense Therapeutics Ltd. | 69 subjects with ALS will be enrolled in the study and randomized at a 2:1 ratio to receive the study drug or placebo tablets. Randomization sequences will be in random block sizes and stratified for ENCALS risk category \[high risk ≥ -4.5 vs. low risk \< -4.5\], and for background ALS treatment (riluzole and/or edarav... | [
{
"type": "DRUG",
"name": "PrimeC"
},
{
"type": "DRUG",
"name": "Placebo"
}
] | 2022-05-31 | https://clinicaltrials.gov/study/NCT05357950 | [
"oxidative_stress"
] | [
{
"facility": "Lawson Health Research Institute",
"city": "London",
"state": "Ontario",
"country": "Canada",
"status": "",
"lat": 42.98339,
"lon": -81.23304
},
{
"facility": "Tel Aviv Sourasky Medical Center",
"city": "Tel Aviv",
"state": "",
"country": "Israel",
... | {
"criteria": "Inclusion Criteria:\n\n1. Able to comprehend and willing to sign an informed consent form (ICF)\n2. Males or females between the ages of 18 and 75 years of age, inclusive\n3. Diagnosis of familial or sporadic ALS (defined as meeting the laboratory-supported probable, probable, or definite criteria for ... | {
"compound": "PrimeC",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT05724173 | Feasibility of the BrainGate2 Neural Interface System in Persons With Tetraplegia | NA | RECRUITING | INTERVENTIONAL | false | Leigh R. Hochberg, MD, PhD. | The purpose of this study is to obtain preliminary device safety information and demonstrate proof of principle (feasibility) of the ability of people with tetraplegia to control a computer cursor and other assistive devices with their thoughts. | [
{
"type": "DEVICE",
"name": "BrainGate Neural Interface System"
}
] | 2023-10-18 | https://clinicaltrials.gov/study/NCT05724173 | [] | [
{
"facility": "Stanford University School of Medicine",
"city": "Stanford",
"state": "California",
"country": "United States",
"status": "RECRUITING",
"lat": 37.42411,
"lon": -122.16608
},
{
"facility": "Massachusetts General Hospital",
"city": "Boston",
"state": "Massach... | 617-724-9247 | lhochberg@mgh.harvard.edu | {
"criteria": "Inclusion Criteria:\n\n* Between 18 and 80 years of age.\n* Participants must have a diagnosis of amyotrophic lateral sclerosis (ALS) as verified by a clinical expert in neurologic diseases.\n* Participants with a diagnosis of ALS with anarthria, or severe dysarthria with decline in the preceding four ... | {
"compound": "BrainGate Neural Interface System",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} |
NCT05949294 | Study of AROSOD-1 in Adult Participants With Amyotrophic Lateral Sclerosis (ALS) | PHASE1 | WITHDRAWN | INTERVENTIONAL | false | Arrowhead Pharmaceuticals | In this Phase 1 adult symptomatic patients with amyotrophic lateral sclerosis (ALS) carrying a superoxide dismutase 1 (SOD1) gene mutation thought to be causative of ALS, will receive single ascending doses of ARO-SOD1 administered by intrathecal (IT) infusion. The study is primarily intended to evaluate safety, but wi... | [
{
"type": "DRUG",
"name": "ARO-SOD1 Injection"
}
] | 2024-01 | https://clinicaltrials.gov/study/NCT05949294 | [
"SOD1"
] | [] | {
"criteria": "Inclusion Criteria:\n\n* Diagnosis of ALS based on source-verifiable medical record and meets the Gold Coast Criteria\n* Pathogenic or likely pathogenic SOD1 mutation based on source-verifiable medical records or genetic testing during Screening\n* Slow Vital Capacity (SVC) ≥ 50% of predicted value adj... | {
"compound": "ARO-SOD1",
"targeting_mechanism": "Reduces SOD1 mRNA and protein levels in patients with SOD1-mediated ALS by delivering a microRNA targeting SOD1 via intrathecal infusion.",
"targeting_mechanism_pmid": "32640133",
"animal_results": "Spinal cord SOD1 levels were lower in treated patients compared... | ||
NCT05193994 | Triumeq in Amyotrophic Lateral Sclerosis | PHASE3 | TERMINATED | INTERVENTIONAL | false | Macquarie University, Australia | To determine if Triumeq improves survival in Amyotrophic Lateral Sclerosis (ALS) compared with placebo | [
{
"type": "DRUG",
"name": "Dolutegravir, Abacavir and Lamivudine"
},
{
"type": "DRUG",
"name": "Placebo"
}
] | 2022-02-24 | https://clinicaltrials.gov/study/NCT05193994 | [
"Integrase"
] | [
{
"facility": "MQ Health Neurology",
"city": "North Ryde",
"state": "New South Wales",
"country": "Australia",
"status": "",
"lat": -33.79677,
"lon": 151.12436
},
{
"facility": "Neuroscience Research Australia (NeuRA)",
"city": "Randwick",
"state": "New South Wales",
... | {
"criteria": "Inclusion Criteria:\n\n1. Age ≥ 18 years at the time of screening\n2. Diagnosis of ALS according to the Gold Coast Criteria\n3. Capable of providing informed consent and complying with trial procedures\n4. TRICALS risk profile \\> -6.0 and \\< -2.0\n5. Those taking Riluzole must be on a stable dose for... | {
"compound": "Triumeq (dolutegravir, abacavir, and lamivudine)",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT07088159 | Intermediate-size Patient Population Expanded Access Protocol | Expanded Access | AVAILABLE | EXPANDED_ACCESS | true | Spinogenix | The purpose of this Expanded Access Program is to provide tazbentetol to ALS patients who are not eligible to enroll in an ALS clinical trial. This Expanded Access Program will assess safety and tolerability, and clinical efficacy of tazbentelol. | [
{
"type": "DRUG",
"name": "Tazbentetol"
}
] | https://clinicaltrials.gov/study/NCT07088159 | [
"tazbentetol"
] | [
{
"facility": "University of Alabama Birmingham",
"city": "Birmingham",
"state": "Alabama",
"country": "United States",
"status": "AVAILABLE",
"lat": 33.52066,
"lon": -86.80249
},
{
"facility": "Mayo Scottsdale",
"city": "Scottsdale",
"state": "Arizona",
"country": "U... | 1 (661) 862-7122 | als302eap@cbcc.global | {
"criteria": "Inclusion Criteria:\n\n* ALS diagnosis\n* Age 18 -85 years at time of signing informed consent form\n* Ineligible for other interventional ALS clinical research participation\n* Vital Capacity greater than 35% of predicted capacity for age, height, and sex\n* If currently taking standard of care treatm... | {
"compound": "Tazbentetol",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | |
NCT01776970 | Safety and Efficacy on Spasticity Symptoms of a Cannabis Sativa Extract in Motor Neuron Disease | PHASE2, PHASE3 | COMPLETED | INTERVENTIONAL | false | Ospedale San Raffaele | The clinical primary hypothesis is that there will be a difference between a Cannabis Sativa extract and placebo in their effect on spasticity in Motor Neuron Disease (MND) patients with signs of involvement of the upper motor neuron (UMN) resulting in disabling spasticity.
Secondary goals of the study are to evidence... | [
{
"type": "DRUG",
"name": "Cannabis Sativa extract Oromucosal spray"
}
] | 2013-01 | https://clinicaltrials.gov/study/NCT01776970 | [
"spasticity"
] | [
{
"facility": "San Raffaele Scientific Institute",
"city": "Milan",
"state": "",
"country": "Italy",
"status": "",
"lat": 45.46427,
"lon": 9.18951
},
{
"facility": "Fondazione Salvatore Maugeri IRCCS, Istituto Scientifico",
"city": "Milan",
"state": "",
"country": "It... | {
"criteria": "Inclusion criteria:\n\nSubjects must fulfil ALL of the following criteria:\n\n* Written informed consent\n* Subject able and willing to comply with all study requirements\n* Affected by ALS, either of definite, probable or possible category according to the El Escorial revised criteria or by primary la... | {
"compound": "Cannabis Sativa extract (oromucosal spray)",
"targeting_mechanism": "Activates cannabinoid receptors, particularly CB2 receptors in reactive astrocytes, to modulate neuroinflammation in motor neuron disease.",
"targeting_mechanism_pmid": "28069688",
"animal_results": "CB2 receptors are upregulate... | ||
NCT05306457 | CNS10-NPC-GDNF Delivered to the Motor Cortex for ALS | PHASE1 | ACTIVE_NOT_RECRUITING | INTERVENTIONAL | false | Cedars-Sinai Medical Center | The investigator is examining the safety of transplanting cells, that have been engineered to produce a growth factor, into the motor cortex (brain) of patients with Amyotrophic Lateral Sclerosis (ALS). The cells are called neural progenitor cells, which are a type of stem cell that can become several different types o... | [
{
"type": "BIOLOGICAL",
"name": "CNS10-NPC-GDNF"
}
] | 2022-05-08 | https://clinicaltrials.gov/study/NCT05306457 | [
"GDNF"
] | [
{
"facility": "Cedars-Sinai Medical Center",
"city": "Los Angeles",
"state": "California",
"country": "United States",
"status": "",
"lat": 34.05223,
"lon": -118.24368
}
] | {
"criteria": "Inclusion:\n\n1. Confirmed diagnosis of ALS (Possible, Lab-supported Probable, Probable or Definite El Escorial Criteria)\n2. Duration of ALS symptoms ≤ 36 months\n3. Progressive weakness in upper extremities, with EMG supported evidence of denervation in both upper extremities\n4. Forced Vital Capacit... | {
"compound": "CNS10-NPC-GDNF (neural progenitor cells engineered to secrete glial cell line-derived neurotrophic factor)",
"targeting_mechanism": "Transplanted neural progenitor cells differentiate into astrocytes and secrete GDNF to provide neuroprotection and support motor neuron survival.",
"targeting_mechani... | ||
NCT07521930 | Interfacing With NeuroTechnology to Expand Neural Throughput (INTENT) | NA | RECRUITING | INTERVENTIONAL | false | Johns Hopkins University | The goal of this clinical trial is to evaluate the safety and preliminary efficacy of an implantable device that records and stimulates different areas of the brain to allow adults affected by disabling paralysis (see Eligibility for more details) to control and receive feedback from assistive devices. | [
{
"type": "DEVICE",
"name": "INTENT Neural Interface System"
}
] | 2026-09 | https://clinicaltrials.gov/study/NCT07521930 | [] | [
{
"facility": "Johns Hopkins Medicine",
"city": "Baltimore",
"state": "Maryland",
"country": "United States",
"status": "RECRUITING",
"lat": 39.29038,
"lon": -76.61219
}
] | 4109559441 | ncrone@jhmi.edu | {
"criteria": "Inclusion Criteria:\n\n* Complete or incomplete tetraplegia (quadriplegia), tetraparesis (quadriparesis), severe ataxia, or disabling motor impairments in both upper limbs, based on neurological exam. In addition, these motor impairments may be combined with severe motor-related speech impairment (dysa... | {
"compound": "unknown",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurposed",
"repurposed_from_pmid": ""
} |
NCT02588807 | Food Supplement for the Treatment of Patients With Amyotrophic Lateral Sclerosis | PHASE1 | WITHDRAWN | INTERVENTIONAL | false | Herb Spirit | The purpose of the study is to evaluate the safety of combining phospholipids with medicinal plants for treatment of patients with amyotrophic lateral sclerosis (ALS) | [
{
"type": "DRUG",
"name": "Spirit1"
}
] | 2021-01-01 | https://clinicaltrials.gov/study/NCT02588807 | [
"neuroinflammation"
] | [
{
"facility": "Hacarmel Hospital",
"city": "Haifa",
"state": "",
"country": "Israel",
"status": "",
"lat": 32.81303,
"lon": 34.99928
}
] | {
"criteria": "Inclusion Criteria:\n\n1. Males aged 18 to 75 years, Females\\>50 years\n2. Diagnosis of \"probable\" or \"definite\" ALS according to the El Escorial revised criteria\n3. A documented history of ALS symptoms for more than 6 month prior to study enrolment, and no more than 40 month.\n4. Patients capabl... | {
"compound": "Spirit1",
"targeting_mechanism": "Reduces neuroinflammation in the CNS to slow ALS progression.",
"targeting_mechanism_pmid": "28872464",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT07589764 | Pilot Trial Utilizing β-hydroxy-β-methylbutyrate to Lower IGFBP7 Levels in People With ALS | PHASE1 | NOT_YET_RECRUITING | INTERVENTIONAL | false | Duke University | This is an open label trial of a supplement called HMB in patients with ALS. The researchers are evaluating its safety and tolerability, as well as its ability to lower insulin-like growth-factor binding protein 7 (IGFBP7) and Neurofilament light chain levels (NFL) and to slow ALS Functional Rating Scale, Revised (ALSF... | [
{
"type": "DRUG",
"name": "β-hydroxy-β-methylbutyrate (HMB)"
}
] | 2026-10-01 | https://clinicaltrials.gov/study/NCT07589764 | [
"IGFBP7"
] | [
{
"facility": "Duke University Medical Center",
"city": "Durham",
"state": "North Carolina",
"country": "United States",
"status": "",
"lat": 35.99403,
"lon": -78.89862
},
{
"facility": "Temple University",
"city": "Philadelphia",
"state": "Pennsylvania",
"country": "... | 919-613-2681 | alsresearch@duke.edu | {
"criteria": "Inclusion Criteria:\n\n1. Male or female aged at least 18 years.\n2. Sporadic or familial ALS diagnosed as per Gold Coast Criteria (37).\n3. Patient is able to understand and express informed consent (in the opinion of the site investigator).\n4. Patient is able to read and write English.\n5. Patient i... | {
"compound": "β-hydroxy-β-methylbutyrate (HMB)",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} |
NCT07187388 | Investigating the Impact of Electrical Stimulation on Facial Pain, Jaw Movement and Oral Health in People With Motor Neuron Disease. | NA | RECRUITING | INTERVENTIONAL | false | Nova Southeastern University | The goal of this clinical trial is to evaluate the impact of non-invasive electrical stimulation, when placed on the facial muscles can reduce facial pain and improve jaw mobility, and chewing in individuals with Amyotrophic Lateral Sclerosis (ALS) and Primary Lateral Sclerosis (PLS). The secondary goal is to evaluate ... | [
{
"type": "DEVICE",
"name": "Transcutaneous Electrical Nerve Stimulation to reduce facial pain and improve jaw range of motion in ALS and PLS"
}
] | 2026-04-02 | https://clinicaltrials.gov/study/NCT07187388 | [] | [
{
"facility": "Nova Southeastern University, David and Cathy Husman Neuroscience Institute",
"city": "Davie",
"state": "Florida",
"country": "United States",
"status": "RECRUITING",
"lat": 26.06287,
"lon": -80.2331
}
] | 954-817-5730 | kayla.chomko@nova.edu | {
"criteria": "Inclusion Criteria:\n\n* Diagnosis of possible, probable, or definite ALS (El-Escorial Revisited) OR diagnosis of definite PLS by the treating neurologist and based on the consensus diagnostic criteria for PLS\n* Subjective report of jaw pain, indicated by a NRS score of \\> or = 3/10.\n\nExclusion Cri... | {
"compound": "unknown",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurposed",
"repurposed_from_pmid": ""
} |
NCT05218668 | Rho Kinase Inhibitor in Amyotrophic Lateral Sclerosis (REAL) | PHASE2 | ACTIVE_NOT_RECRUITING | INTERVENTIONAL | false | Woolsey Pharmaceuticals | A Phase 2a Open-Label Preliminary Safety, Efficacy, and Biomarker Study of WP-0512 in Patients with Amyotrophic Lateral Sclerosis (ALS) | [
{
"type": "DRUG",
"name": "Fasudil (WP-0512)"
},
{
"type": "DRUG",
"name": "Fasudil (WP-0512)"
}
] | 2021-12-22 | https://clinicaltrials.gov/study/NCT05218668 | [
"ROCK"
] | [
{
"facility": "Neuromuscular Research Center",
"city": "Phoenix",
"state": "Arizona",
"country": "United States",
"status": "",
"lat": 33.44838,
"lon": -112.07404
},
{
"facility": "University of Colorado",
"city": "Aurora",
"state": "Colorado",
"country": "United Stat... | {
"criteria": "Inclusion Criteria:\n\n1. Between 18 and 75 years of age (inclusive) at Screening 1.\n2. Subject has had a diagnosis of probable laboratory-supported, probable, or definite ALS (as defined by El Escorial Revised ALS diagnostic criteria) by Screening 1, and no other cause of the neurological impairment ... | {
"compound": "Fasudil (WP-0512)",
"targeting_mechanism": "Rho kinase inhibitor with neuroprotective and anti-inflammatory effects.",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT02464852 | Assessment of the Effects of Sheffield Support Snood in MND Patients | NA | COMPLETED | INTERVENTIONAL | false | Sheffield Teaching Hospitals NHS Foundation Trust | The aim of this study is to evaluate the effects on MND patients of a new collar specifically designed for people affected by neck weakness: the Sheffield Support Snood. | [
{
"type": "BEHAVIORAL",
"name": "Head movements"
},
{
"type": "BEHAVIORAL",
"name": "Activities of daily living (drinking, washing hand and eating)"
},
{
"type": "DEVICE",
"name": "Sheffield Support Snood"
},
{
"type": "DEVICE",
"name": "sEMG"
}
] | 2015-04 | https://clinicaltrials.gov/study/NCT02464852 | [] | [
{
"facility": "Royal Hallamshire Hospital",
"city": "Sheffield",
"state": "South Yorkshire",
"country": "United Kingdom",
"status": "",
"lat": 53.38297,
"lon": -1.4659
}
] | {
"criteria": "Inclusion Criteria:\n\n* Clinical status consistent with MND\n* Capability to understand instructions\n* Capability to perform testing procedures\n* Ability to give informed consent\n\nExclusion Criteria:\n\n* Presence of any inflammatory or other disease involving joint or muscle pathology that might ... | {
"compound": "unknown",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurposed",
"repurposed_from_pmid": ""
} | ||
NCT01569958 | Transcranial Direct Current Stimulation as a Novel Therapeutic Approach in Amyotrophic Lateral Sclerosis | PHASE2 | UNKNOWN | INTERVENTIONAL | false | Università degli Studi 'G. d'Annunzio' Chieti e Pescara | Amyotrophic Lateral Sclerosis (ALS) is a neurodegenerative disease characterized by progressive weakness and muscular atrophy due to the degeneration and loss of motor neurons, the nerve cells that, in the central nervous system (motor cortex, brainstem and spinal chord), control voluntary movement. Riluzole, the only ... | [
{
"type": "OTHER",
"name": "transcranial direct current stimulation"
},
{
"type": "OTHER",
"name": "Sham stimulation"
}
] | 2012-07 | https://clinicaltrials.gov/study/NCT01569958 | [] | [
{
"facility": "Centro Regionale Malattie Neuromuscolari, Ospedale Clinicizzato \"SS. Annunziata\"",
"city": "Chieti",
"state": "Chieti",
"country": "Italy",
"status": "RECRUITING",
"lat": 42.34827,
"lon": 14.16494
},
{
"facility": "Azienda Policlinico Università Federico II",
... | {
"criteria": "Inclusion Criteria:\n\n* diagnosis of probable, laboratory-supported probable, or definite amyotrophic lateral sclerosis according to the El Escorial revised criteria\n* spinal onset\n* aged 18 to 85 years inclusive\n* disease duration ≤ 24 months\n* disease progression in the past 3 months\n* FVC ≥ 70... | {
"compound": "transcranial direct current stimulation (tDCS)",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurposed",
"repurposed_from_pmid": ""
} | ||
NCT01530438 | Study of Cognitive and Emotional Disorders in Amyotrophic Lateral Sclerosis | NA | UNKNOWN | INTERVENTIONAL | false | University Hospital, Caen | Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease that involves not only motor structures, as was previously thought, but also brain areas dealing with cognition as well as parts of the limbic system. Clinical, imaging and pathological evidence suggests that ALS and fronto-temporal dementia (FTD) have ... | [
{
"type": "OTHER",
"name": "MRI + 18FDG-PET + neuropsychological assessments ; 18FDG performed especially for the research"
}
] | 2009-04 | https://clinicaltrials.gov/study/NCT01530438 | [] | [
{
"facility": "University Hospital Center",
"city": "Caen",
"state": "",
"country": "France",
"status": "RECRUITING",
"lat": 49.18585,
"lon": -0.35912
},
{
"facility": "University Hospital Center",
"city": "Rouen",
"state": "",
"country": "France",
"status": "ACTI... | {
"criteria": "Inclusion Criteria:\n\n* All participants :\n\n * study level \\> 7 years\n * mother tongue : french\n * signature of the informed consent of the protocol in accord with the Comité de Protection des Personnes\n * medical, neurological, neuroradiological and neuropsychological approfondis in accord ... | {
"compound": "unknown",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurposed",
"repurposed_from_pmid": ""
} | ||
NCT03766321 | Fecal Microbiota Transplantation Effect on Amyotrophic Lateral Sclerosis Patients | NA | COMPLETED | INTERVENTIONAL | false | Azienda Ospedaliero-Universitaria di Modena | Given the role of adaptive immunity in ALS, the pathogenicity of some clostridial strains on motorneurons, the putative role of cyanobacteria in ALS development, and the increasing interest for microbiota in neurodegenerative disorders, the modification of intestinal microbiota might affect ALS at its core.
This inter... | [
{
"type": "BIOLOGICAL",
"name": "Fecal microbiota transplantation"
},
{
"type": "BIOLOGICAL",
"name": "Placebo"
}
] | 2020-07-01 | https://clinicaltrials.gov/study/NCT03766321 | [
"microbiota"
] | [
{
"facility": "Catholic University of Sacred Heart - Fondazione Policlinico \"A. Gemelli\"",
"city": "Roma",
"state": "Italy",
"country": "Italy",
"status": "",
"lat": 44.99364,
"lon": 11.10642
},
{
"facility": "Clinica Neurologica, Ospedale Clinicizzato \"SS Annunziata\"",
"... | {
"criteria": "Inclusion Criteria:\n\n* Patients diagnosed with a laboratory supported, clinically \"probable\" or \"definite\" amyotrophic lateral sclerosis according to the Revised El Escorial criteria (Brooks, 2000)\n* Sporadic or familial ALS\n* Female or male patients aged between 18 and 70 years old\n* Disease ... | {
"compound": "Fecal Microbiota Transplantation (FMT)",
"targeting_mechanism": "Modification of intestinal microbiota composition to target dysbiosis and reduce pro-inflammatory mediators implicated in ALS pathogenesis.",
"targeting_mechanism_pmid": "28947596",
"animal_results": "In the SOD1(G93A) ALS mouse mod... | ||
NCT01257581 | Safety and Efficacy Study of Creatine and Tamoxifen in Volunteers With Amyotrophic Lateral Sclerosis (ALS) | PHASE2 | COMPLETED | INTERVENTIONAL | false | Nazem Atassi | The purpose of the study is to evaluate the safety and efficacy of high dose creatine and two dosages of tamoxifen treatment in amyotrophic lateral sclerosis (ALS). | [
{
"type": "DRUG",
"name": "creatine"
},
{
"type": "DRUG",
"name": "tamoxifen"
}
] | 2011-03 | https://clinicaltrials.gov/study/NCT01257581 | [
"mitochondrial_function",
"Estrogen receptor"
] | [
{
"facility": "University of Kansas Medical Center",
"city": "Kansas City",
"state": "Kansas",
"country": "United States",
"status": "",
"lat": 39.11417,
"lon": -94.62746
},
{
"facility": "Massachusetts General Hospital",
"city": "Boston",
"state": "Massachusetts",
"c... | {
"criteria": "Inclusion Criteria:\n\n* Familial or sporadic ALS.\n* Disease duration from diagnosis no greater than 36 months at Screening Visit.\n* Aged 18 years or older.\n* Capable of providing informed consent and complying with trial procedures.\n* Vital capacity (VC) equal to or more than 50% predicted normal ... | {
"compound": "creatine and tamoxifen",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.